What's new

Kava Research Master List of Kava Research Articles (Currently 607)

Kapmcrunk

The Kaptain (40g)
KavaForums Founder
’Apo' Aporosa, S. 2015. “The New Kava User: Diasporic Identity Formation in Reverse.” New Zealand Sociology 30 (4): 58–77.

(Apo) Aporosa, S., and Matt Tomlinson. 2014. “Kava Hangover and Gold-Standard Science.” Anthropologica 56 (1): 163–75. https://doi.org/10.1353/ant.2014.0014.

Abdel Jaleel, Gehad A., Dalia O. Saleh, and Sally A. El-Awdan. 2013. “Antihyperglycaemic Effect of Kava Kava (piper Methysticum) in Streptozotocin- Induced Diabetic Rats.” Der Pharmacia Lettre 5 (5): 104–10.

Abu, Nadiah, M. Nadeem Akhtar, Swee Keong Yeap, Kian Lam Lim, Wan Yong Ho, Aimi Jamil Zulfadli, Abdul Rahman Omar, Mohd Roslan Sulaiman, Mohd Puad Abdullah, and Noorjahan Banu Alitheen. 2014. “Flavokawain A Induces Apoptosis in MCF-7 and MDA-MB231 and Inhibits the Metastatic Process in Vitro.” PloS One 9 (10): e105244. https://doi.org/10.1371/journal.pone.0105244.

Abu, Nadiah, Wan Yong Ho, Swee Keong Yeap, M. Nadeem Akhtar, Mohd Puad Abdullah, Abdul Rahman Omar, and Noorjahan Banu Alitheen. 2013. “The Flavokawains: Uprising Medicinal Chalcones.” Cancer Cell International 13 (1): 102. https://doi.org/10.1186/1475-2867-13-102.

Abu, Nadiah, Nurul Elyani Mohamed, Swee Keong Yeap, Kian Lam Lim, M. Nadeem Akhtar, Aimi Jamil Zulfadli, Beh Boon Kee, Mohd Puad Abdullah, Abdul Rahman Omar, and Noorjahan Banu Alitheen. 2015. “In Vivo Antitumor and Antimetastatic Effects of Flavokawain B in 4T1 Breast Cancer Cell-Challenged Mice.” Drug Design, Development and Therapy 9 (March): 1401–17. https://doi.org/10.2147/DDDT.S67976.

Abu, Nadiah, Nurul Elyani Mohameda, Nirosha Tangarajoo, Swee Keong Yeap, M. Nadeem Akhtar, Mohd Puad Abdullah, Abdul Rahman Omar, and Noorjahan Banu Alitheen. 2015. “In Vitro Toxicity and in Vivo Immunomodulatory Effects of Flavokawain A and Flavokawain B in Balb/C Mice.” Natural Product Communications 10 (7): 1199–1202. https://doi.org/10.1177/1934578X1501000716.

Ambrose, W. 1991. “Manus, Mortars and the Kava Concoction.” https://www.semanticscholar.org/paper/097e6b89e9b9b7cd01a76f4f8bc07e300fbca9ca.

Amdidouche-Hussain’I, Didja, and Joel Levesque. 1997. “Selection of Kavalactones by Complexation of Kava Extract with C Yclodextrins.” Drug Development and Industrial Pharmacy 23 (12): 1223–26. https://doi.org/10.3109/03639049709146161.

Anke, J., S. Fu, and I. Ramzan. 2006. “Kavalactones Fail to Inhibit Alcohol Dehydrogenase in Vitro.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 13 (3): 192–95. https://doi.org/10.1016/j.phymed.2004.07.005.

Anke, Jennifer, and Iqbal Ramzan. 2004a. “Pharmacokinetic and Pharmacodynamic Drug Interactions with Kava (Piper Methysticum Forst. F.).” Journal of Ethnopharmacology 93 (2-3): 153–60. https://doi.org/10.1016/j.jep.2004.04.009.

Anke, Jennifer, and Iqqbal Ramzan. 2004b. “Kava Hepatotoxicity: Are We Any Closer to the Truth?” Planta Medica 70: 193–96. https://doi.org/10.1055/s-2004-815533.

Apo Aporosa, S. 2011. “Apososa S. ‘Apo’ - 2011 - Is Kava Alcohol The Myths and the Facts.pdf.” Pacific Health Dialog 17 (1): 157–64. https://pubmed.ncbi.nlm.nih.gov/23008981/.

Apo’Aporosa, S. 2015. “Yaqona (kava) as a Symbol of Cultural Identity.” S. ‘. Aporosa.

Aporosa, A. S. 2019. “Kava, the Devil, and the Snake: Pentecostal Iconoclasm in Contemporary Fiji.” University of Auckland.

Aporosa, Apo. 2019. “Australia’s Discussion of Kava Imports Reflects Lack of Cultural Understanding.” The Conversation, June 9, 2019. http://theconversation.com/australi...eflects-lack-of-cultural-understanding-115662.

Aporosa, Apo S., Martin Atkins, and Richard Brunton. 2020. “Kava Drinking in Traditional Settings: Towards Understanding Effects on Cognitive Function.” Human Psychopharmacology 35 (2): e2725. https://doi.org/10.1002/hup.2725.

Aporosa, S. 2017. “Understanding Cognitive Functions Related to Driving Following Kava (Piper Methysticum) Use at Traditional Consumption Volumes.” In British Association for Psychopharmacology Conference, A84–A84. SAGE Publications. https://researchcommons.waikato.ac.nz/handle/10289/11307.

———. 2018. “Improving Road Safety and Health: Understanding Kava’s Impact on Driver Fitness.” University of Waikato. https://researchcommons.waikato.ac.nz/handle/10289/12947.

———. 2019. “Cognitive Functions Associated with Consumption of Traditional Volumes of Kava (Piper Methysticum): A Feasibility Study.” In British Association for Psychopharmacology. researchcommons.waikato.ac.nz. https://researchcommons.waikato.ac.nz/handle/10289/12780.

Aporosa, S. Apo. 2019a. “Kava and Ethno-Cultural Identity in Oceania.” In The Palgrave Handbook of Ethnicity, edited by Steven Ratuva, 1–15. Singapore: Springer Singapore. https://doi.org/10.1007/978-981-13-0242-8_134-1.

———. 2019b. “De-Mythologizing and Re-Branding of Kava as the New ‘world Drug’ of Choice.” Drug Science, Policy and Law 5 (January): 2050324519876131. https://doi.org/10.1177/2050324519876131.

Aporosa, S. Apo, Martin Atkins, and Jess N. Leov. 2021. “Decolonising Quantitative Methods within a Pacific Research Space to Explore Cognitive Effects Following Kava Use.” Journal of Interdisciplinary Research 5 (1). https://doi.org/10.26021/10642.

Aporosa, S. ’apo'. 2014. “YAQONA (KAVA) AND EDUCATION IN FIJI:INVESTIGATING ‘CULTURAL COMPLEXITIES’FROM A POST-DEVELOPMENT PERSPECTIVE.”

Aporosa, S., and Jacinta Forde. 2019. “Māori and Kava: New Drug Fashion or Re-Engagement With’kawa'?” Pacific Dynamics 3 (1): 72–85. https://researchcommons.waikato.ac.nz/handle/10289/12952.

Aporosa, S. G. 2008. Yaqona (Kava) and Education in Fiji: A Clash of Cultures? VDM Verlag.

Ashraf-Khorassani, M., L. T. Taylor, and M. Martin. 1999. “Supercritical Fluid Extraction of Kava Lactones from Kava Root and Their Separation via Supercritical Fluid Chromatography.” Chromatographia 50: 287–92. https://doi.org/10.1007/BF02490830.

Backhaul, Cord, and Josef Krieglstein. 1992. “Extract of Kava ( Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue against Ischemic Damage in Rodents.” European Journal ~>~ Pharmacoloj, % 215: 265269.

Backleh, Marlène, Perihan Ekici, Günther Leupold, and Harun Parlar. 2003. “Quantitative Elimination of Flavokavines A and B from Kava Kava (Piper Methysticum G. Forst) by Isoelectric Focused Adsorptive Bubble Separation.” Die Naturwissenschaften 90 (8): 366–69. https://doi.org/10.1007/s00114-003-0440-5.

Baker, Jonathan D. 2011. “Tradition and Toxicity: Evidential Cultures in the Kava Safety Debate.” Social Studies of Science 41 (3): 361–84. https://doi.org/10.1177/0306312710395341.

———. 2012. “Pills, Potions, Products: Kava’s Transformations in New and Nontraditional Contexts.” The Contemporary Pacific 24 (2): 233–65. https://doi.org/10.1353/cp.2012.0026.

Balick, Michael J., and Roberta Lee. 2002. “Traditional Use of Sakau (kava) in Pohnpei: Lessons for Integrative Medicine.” Alternative Therapies in Health and Medicine 8 (4): 96–98. https://www.ncbi.nlm.nih.gov/pubmed/12126179.

Balick, Michael J & Lee, Robert A. 2009. “The Sacred Root.” In Ethnobotany of Pohnpei, 165–203. University of Hawaii Press.

Barguil, Yann, Erwan Choblet, Sébastien Warter, and Mohammed Nour. 2013. “Kava Ichthyosis: A Nitric Oxide Synthase Inhibition?” Annales de Toxicologie Analytique 25 (4): 165–68. https://doi.org/10.1051/ata/2014001.

Barnes, Joanne, Linda A. Anderson, and J. D. Phillipson. 2007. “Kava - Overview.” In Herbal Medicines, 389–402. 3rd Ed. Grayslake, IL: Pharmaceutical Press.

Bauer, Rudolf, Brigitte & Kopp, and A. Nahrstedt. 2003. “Relevant Hepatotoxic Effects of Kava Still Need to Be Proven: A Statement of the Society for Medicinal Plant Research.” Planta Medica 69 (11): 971–72. https://doi.org/10.1055/s-2003-45140.

Baum, S. S., R. Hill, and H. Rommelspacher. 1998. “Effect of Kava Extract and Individual Kavapyrones on Neurotransmitter Levels in the Nucleus Accumbens of Rats.” Progress in Neuro-Psychopharmacology & Biological Psychiatry 22 (7): 1105–20. https://doi.org/10.1016/s0278-5846(98)00062-1.

Becker, Matheus William, Emerson Matheus Silva Lourençone, Alexandre Formighieri De Mello, Aline Branco, Edison Moraes Rodrigues Filho, Celso Ronaldo Blatt, Carlos Augusto Mallmann, Maurício Schneider, Rita Catalina Aquino Caregnato, and Carine Raquel Blatt. 2019. “Liver Transplantation and the Use of KAVA: Case Report.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 56 (March): 21–26. https://doi.org/10.1016/j.phymed.2018.08.011.

Behl, Mamta, Abraham Nyska, Rajendra S. Chhabra, Gregory S. Travlos, Laurene M. Fomby, Barney R. Sparrow, Milton R. Hejtmancik, and Po C. Chan. 2011. “Liver Toxicity and Carcinogenicity in F344/N Rats and B6C3F1 Mice Exposed to Kava Kava.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 49 (11): 2820–29. https://doi.org/10.1016/j.fct.2011.07.067.

Berry, Jonna, Ashley Gilbert, and Justin Grodnitzky. 2019. “Cases of Kava Impairment in Iowa Drivers.” Journal of Forensic Sciences 64 (6): 1943–49. https://doi.org/10.1111/1556-4029.14130.

BfArM. 2002. “Kava Removal.” http://lrd.spc.int/ahp-publications/doc_download/578-gr-cis-bfarm-kava-removal.

Bian, Tengfei, Pedro Corral, Yuzhi Wang, Jordy Botello, Rick Kingston, Tyler Daniels, Ramzi G. Salloum, et al. 2020. “Kava as a Clinical Nutrient: Promises and Challenges.” Nutrients 12 (10). https://doi.org/10.3390/nu12103044.

Bilia, Anna Rita, Sandra Gallon, and Franco F. Vincieri. 2002. “Kava-Kava and Anxiety: Growing Knowledge about the Efficacy and Safety.” Life Sciences 70 (22): 2581–97. https://doi.org/10.1016/s0024-3205(02)01555-2.

Bilia, Anna Rita, Luca Scalise, Maria Camilla Bergonzi, and Franco F. Vincieri. 2004. “Analysis of Kavalactones from Piper Methysticum (kava-Kava).” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 812 (1-2): 203–14. https://doi.org/10.1016/j.jchromb.2004.07.038.

Bird, Gail. 2016. “Import Restrictions: Kava and Khat.” The Office of Drug Control. December 7, 2016. https://www.odc.gov.au/import-restrictions-kava-and-khat.

Boerner, R. J. 2001. “Kava Kava in the Treatment of Generalized Anxiety Disorder, Simple Phobia and Specific Social Phobia.” Phytotherapy Research: PTR 15 (7): 646–47. https://doi.org/10.1002/ptr.1006.

Boerner, R. J., H. Sommer, W. Berger, U. Kuhn, U. Schmidt, and M. Mannel. 2003. “Kava-Kava Extract LI 150 Is as Effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-Week Randomized, Double-Blind Multi-Centre Clinical Trial in 129 out-Patients.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 10 Suppl 4: 38–49. https://doi.org/10.1078/1433-187x-00309.

Boerner, Reinhard J., and Stephan Klement. 2004. “Attenuation of Neuroleptic-Induced Extrapyramidal Side Effects by Kava Special Extract WS 1490.” Wiener Medizinische Wochenschrift 154 (21-22): 508–10. https://doi.org/10.1007/s10354-004-0115-7.

Boonen, G., B. Ferger, K. Kuschinsky, and H. Häberleinl. 1998. “In Vivo Effects of the Kavapyrones (+)-Dihydromethysticin And(±)-Kavain on Dopamine, 3,4-Dihydroxyphenylacetic Acid, Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Cortical Brain Regions.” Planta Medica 64: 507–10.

Boonen, Georg, and Hanns Hberlein. 1998. “Influence of Genuine Kavapyrone Enantiomerson the GABAA Binding Site.” Planta Medica 64: 504–6.

Botello, Jordy F., Pedro Corral, Tengfei Bian, and Chengguo Xing. 2020. “Kava and Its Kavalactones Inhibit Norepinephrine-Induced Intracellular Calcium Influx in Lung Cancer Cells.” Planta Med 86 (1): 26–31. https://doi.org/10.1055/a-1035-5183.

Brown, Amy C., Janet Onopa, Peter Holck, Pakieli Kaufusi, Derek Kabasawa, Winston J. Craig, Klaus Dragull, Arieh M. Levine, and Jonathan D. Baker. 2007. “Traditional Kava Beverage Consumption and Liver Function Tests in a Predominantly Tongan Population in Hawaii.” Clinical Toxicology 45 (5): 549–56. https://doi.org/10.1080/15563650701365875.

Butt, Julia. 2019. Kava Usage in Aboriginal and Pacific Islander Communities in Australia. National Drug Research Institute.

Cairney, Sheree, Alan R. Clough, Paul Maruff, Alex Collie, Bart J. Currie, and Jon Currie. 2003. “Saccade and Cognitive Function in Chronic Kava Users.” Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 28 (2): 389–96. https://doi.org/10.1038/sj.npp.1300052.

Cairney, Sheree, Paul Maruff, and Alan R. Clough. 2002. “The Neurobehavioural Effects of Kava.” The Australian and New Zealand Journal of Psychiatry 36 (5): 657–62. https://doi.org/10.1046/j.1440-1614.2002.01027.x.

Capasso, A., and L. Sorrentino. 2005. “Pharmacological Studies on the Sedative and Hypnotic Effect of Kava Kava and Passiflora Extracts Combination.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 12 (1-2): 39–45. https://doi.org/10.1016/j.phymed.2004.03.006.

Catchpole, O. J., N. B. Perry, B. M. T. da Silva, J. B. Grey, and B. M. Smallfield. 2002. “Supercritical Extraction of Herbs I: Saw Palmetto, St John’s Wort, Kava Root, and Echinacea.” The Journal of Supercritical Fluids 22 (2): 129–38. https://doi.org/10.1016/S0896-8446(01)00110-3.

Cawte, John. 1986. “Parameters of Kava Used as a Challenge to Alcohol.” The Australian and New Zealand Journal of Psychiatry 20 (1): 70–76. https://doi.org/10.3109/00048678609158867.

Celentano, Antonio, Andrew Tran, Claire Testa, Krishen Thayanantha, William Tan-Orders, Stephanie Tan, Mitali Syamal, Michael J. McCullough, and Tami Yap. 2019. “The Protective Effects of Kava (Piper Methysticum) Constituents in Cancers: A Systematic Review.” Journal of Oral Pathology & Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 48 (7): 510–29. https://doi.org/10.1111/jop.12900.

Celentano, Antonio, Callisthenis Yiannis, Rita Paolini, Pangzhen Zhang, Camile S. Farah, Nicola Cirillo, Tami Yap, and Michael McCullough. 2020. “Kava Constituents Exert Selective Anticancer Effects in Oral Squamous Cell Carcinoma Cells in Vitro.” Scientific Reports 10 (1): 1–11. https://doi.org/10.1038/s41598-020-73058-4.

Chambers, Megan I., Amy M. Osborne, and Rabi A. Musah. 2019. “Rapid Detection and Validated Quantification of Psychoactive Compounds in Complex Plant Matrices by Direct Analysis in Real Time-High Resolution Mass Spectrometry - Application to ‘Kava’ Psychoactive Pepper Products.” Rapid Communications in Mass Spectrometry: RCM 33 (24): 1915–25. https://doi.org/10.1002/rcm.8532.

Chaurasiya, Narayan D., Francisco León, Yuanqing Ding, Isabel Gómez-Betancur, Dora Benjumea, Larry A. Walker, Stephen J. Cutler, and Babu L. Tekwani. 2017. “Interactions of Desmethoxyyangonin, a Secondary Metabolite from Renealmia Alpinia, with Human Monoamine Oxidase-A and Oxidase-B.” Evidence-Based Complementary and Alternative Medicine: eCAM 2017 (August): 4018724. https://doi.org/10.1155/2017/4018724.

Chou, Tsui-Wei, Jia-Hua Feng, Chi-Chang Huang, Ya-Wen Cheng, Shih-Chang Chien, Sheng-Yang Wang, and Lie-Fen Shyur. 2013. “A Plant Kavalactone Desmethoxyyangonin Prevents Inflammation and Fulminant Hepatitis in Mice.” PloS One 8 (10): e77626. https://doi.org/10.1371/journal.pone.0077626.

Chua, Han Chow, Emilie T. H. Christensen, Kirsten Hoestgaard-Jensen, Leonny Y. Hartiadi, Iqbal Ramzan, Anders A. Jensen, Nathan L. Absalom, and Mary Chebib. 2016. “Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism.” PloS One 11 (6): e0157700. https://doi.org/10.1371/journal.pone.0157700.

Clayton, Natasha P., Katsuhiko Yoshizawa, Grace E. Kissling, Leo T. Burka, Po-Chuen Chan, and Abraham Nyska. 2007. “Immunohistochemical Analysis of Expressions of Hepatic Cytochrome P450 in F344 Rats Following Oral Treatment with Kava Extract.” Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Fur Toxikologische Pathologie 58: 223–36. https://doi.org/10.1016/j.etp.2006.08.002.

Clouatre, Dallas L. 2004. “Kava Kava: Examining New Reports of Toxicity.” Toxicology Letters 150: 85–96. https://doi.org/10.1016/j.toxlet.2003.07.005.

Clough, A. R., S. P. Jacups, Z. Wang, C. B. Burns, R. S. Bailie, S. J. Cairney, A. Collie, T. Guyula, S. P. McDonald, and B. J. Currie. 2003. “Health Effects of Kava Use in an Eastern Arnhem Land Aboriginal Community.” Internal Medicine Journal 33 (8): 336–40. https://doi.org/10.1046/j.1444-0903.2003.00405.x.

Clough, A. R., K. Rowley, and K. O’Dea. 2004. “Kava Use, Dyslipidaemia and Biomarkers of Dietary Quality in Aboriginal People in Arnhem Land in the Northern Territory (NT), Australia.” European Journal of Clinical Nutrition 58 (7): 1090–93. https://doi.org/10.1038/sj.ejcn.1601921.

Clough, Alan. 2003. “Enough! Or Too Much. What Is ‘Excessive’ Kava Use in Arnhem Land?” Drug and Alcohol Review 22 (1): 43–51. https://doi.org/10.1080/0959523021000059820.

Clough, Alan R., Sheree Cairney, Paul Maruff, Chris B. Burns, and Bart J. Currie. 2001. “Possible Toxicity and Withdrawal Seizures in Aboriginal Kava Drinkers in Arnhem Land, (Australia).” South Pacific Journal of Psychology 13: 26–33. https://doi.org/10.1017/S025754340000033X.

Connell, John. 2007. “Towards Free Trade in the Pacific? The Genesis of the ‘Kava-Biscuit War’ between Fiji and Vanuatu.” Geographical Research 45 (1): 1–12. https://doi.org/10.1111/j.1745-5871.2007.00425.x.

Connor, K. M., J. R. Davidson, and L. E. Churchill. 2001. “Adverse-Effect Profile of Kava.” CNS Spectrums 6 (10): 848, 850–53. https://doi.org/10.1017/s109285290000167x.

Connor, K. M., and J. R. T. Davidson. 2002. “A Placebo-Controlled Study of Kava Kava in Generalized Anxiety Disorder.” International Clinical Psychopharmacology 17 (4): 185–88. https://doi.org/10.1097/00004850-200207000-00005.

Connor, Kathryn M., Victoria Payne, and Jonathan R. T. Davidson. 2006. “Kava in Generalized Anxiety Disorder: Three Placebo-Controlled Trials.” International Clinical Psychopharmacology 21 (5): 249–53. https://doi.org/10.1097/00004850-200609000-00001.

Costa, Willian Richardes, Lucas Rossi Sartori, and José C. Tavares Carvalho. 2010. “Study of In Vitro and In Vivo Extraction of Kavalactones of Pharmaceutical Form Containing Ground Plant Drug (Piper Methysticum G. Forster).” Latin American Journal of Pharmacy 29 (2): 289–92. https://www.academia.edu/download/49124391/Kavalactones_LAJP.pdf.

Côté, Cynthia S., Christine Kor, Jon Cohen, and Karine Auclair. 2004. “Composition and Biological Activity of Traditional and Commercial Kava Extracts.” Biochemical and Biophysical Research Communications 322 (1): 147–52. https://doi.org/10.1016/j.bbrc.2004.07.093.

Coulter, David, Tamayo Carmen Sotheeswaran Subramaniam, Catherine Ulbricht, and World Health Organization. 2007. “Assessment of the Risk of Hepatotoxicity with Kava Products.pdf.” World Health Organization.

Cox, Paul Alan, and Lisa O’Rourke. 1987. “Kava (Piper Methysticum, Piperaceae).” Economic Botany 41 (3): 452–54. http://www.jstor.org/stable/4254999.

D. Schmitz ,CL Zhang ,SS Chatterjee &U. Heinemann. 1995. “Effects of Methysticin on Three Different Models of Seizure like Events Studied in Rat Hippocampal and Entorhinal Cortex Slices.” Naunyn-Schmiedeberg’s Archives of Pharmacology 351: 348–55. https://doi.org/10.1007/BF00169074.

Dai, Jun-Qi, Yi-Gang Huang, and Ai-Na He. 2015. “Dihydromethysticin Kavalactone Induces Apoptosis in Osteosarcoma Cells through Modulation of PI3K/Akt Pathway, Disruption of Mitochondrial Membrane Potential and Inducing Cell Cycle Arrest.” International Journal of Clinical and Experimental Pathology 8 (5): 4356–66. https://www.ncbi.nlm.nih.gov/pubmed/26191127.

Danan, Gaby, and Rolf Teschke. 2015. “RUCAM in Drug and Herb Induced Liver Injury: The Update.” International Journal of Molecular Sciences 17 (1). https://doi.org/10.3390/ijms17010014.

Davies, L. P., C. A. Drew, P. Duffield, G. A. Johnston, and D. D. Jamieson. 1992. “Kava Pyrones and Resin: Studies on GABAA, GABAB and Benzodiazepine Binding Sites in Rodent Brain.” Pharmacology & Toxicology 71 (2): 120–26. https://doi.org/10.1111/j.1600-0773.1992.tb00530.x.

De Leo, V., A. la Marca, G. Morgante, D. Lanzetta, P. Florio, and F. Petraglia. 2001. “Evaluation of Combining Kava Extract with Hormone Replacement Therapy in the Treatment of Postmenopausal Anxiety.” Maturitas 39 (2): 185–88. https://doi.org/10.1016/s0378-5122(01)00197-9.

Denery, Judith R., Klaus Dragull, C. S. Tang, and Qing X. Li. 2004. “Pressurized Fluid Extraction of Carotenoids from Haematococcus Pluvialis and Dunaliella Salina and Kavalactones from Piper Methysticum.” Analytica Chimica Acta 501 (2): 175–81. https://doi.org/10.1016/j.aca.2003.09.026.

Denham, Alison, Michael McIntyre, and Julie Whitehouse. 2002. “Kava—the Unfolding Story: Report on a Work-in-Progress.” The Journal of Alternative and Complementary Medicine 8 (3): 237–63. https://doi.org/10.1089/10755530260127943.

Dentali, Steven J., Cristina Amarillas, Tyler Blythe, Paula N. Brown, Anton Bzhelyansky, Christine Fields, Holly E. Johnson, et al. 2018. “Standard Method Performance Requirements (SMPRs®) 2018.005: Determination of Kavalactones And/or Flavokavains from Kava (Piper Methysticum).” Journal of AOAC International 101 (4): 1256–60. https://doi.org/10.5740/jaoacint.smpr2018.005.

Department of Industry, Tourism and Trade. 2020. “KAVA MANAGEMENT ACT 1998.” https://legislation.nt.gov.au/Legislation/KAVA-MANAGEMENT-ACT-1998.

Dharmaratne, H. Ranjith W., N. P. Dhammika Nanayakkara, and Ikhlas A. Khan. 2002. “Kavalactones from Piper Methysticum, and Their 13C NMR Spectroscopic Analyses.” Phytochemistry 59 (4): 429–33. https://doi.org/10.1016/s0031-9422(01)00443-5.

Dietlein, G., and D. Schröder-Bernhardi. 2003. “Doctors’ Prescription Behaviour Regarding Dosage Recommendations for Preparations of Kava Extracts.” Pharmacoepidemiology and Drug Safety 12 (5): 417–21. https://doi.org/10.1002/pds.839.

Dinh, L. D., U. Simmen, K. B. Bueter, B. Bueter, K. Lundstrom, and W. Schaffner. 2001. “Interaction of Various Piper Methysticum Cultivars with CNS Receptors in Vitro.” Planta Medica 67 (4): 306–11. https://doi.org/10.1055/s-2001-14334.

DiSilvestro, Robert A., Wenyi Zhang, and David J. DiSilvestro. 2007. “Kava Feeding in Rats Does Not Cause Liver Injury nor Enhance Galactosamine-Induced Hepatitis.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 45 (7): 1293–1300. https://doi.org/10.1016/j.fct.2007.01.015.

Einbond, L. S., A. Negrin, D. M. Kulakowski, H-A Wu, V. Antonetti, F. Jalees, W. Law, et al. 2017. “Traditional Preparations of Kava (Piper Methysticum) Inhibit the Growth of Human Colon Cancer Cells in Vitro.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 24 (January): 1–13. https://doi.org/10.1016/j.phymed.2016.11.002.

Ernst, E. 2007. “A Re-Evaluation of Kava (Piper Methysticum).” British Journal of Clinical Pharmacology 64 (4): 415–17. https://doi.org/10.1111/j.1365-2125.2007.02932.x.

Ernst, Edzard. 2002. “Second Thoughts about Kava.” The American Journal of Medicine 113 (4): 347–48. https://doi.org/10.1016/S0002-9343(02)01204-4.

Fehoko, E. 2013. “From Kava to Coffee: Tongan Young People in Auckland.” Mana Ngākau: Community Compassion Māori and. https://www.academia.edu/download/33781543/From_Kava_to_Coffee_Tongan_Young_People_in_Auckland.pdf.

Fehoko, E., I. Hafoka, and A. Tecun. 2021. “Holding Tightly onto Land and People During a Pandemic: Kava Pedagogies and Tertiary Learning Relationships in Vahaope.” Researchgate.net. https://www.researchgate.net/profil...ertiary-Learning-Relationships-in-Vahaope.pdf.

Feltenstein, Matt W., L. Corinne Lambdin, M. Ganzera, H. Ranjith, W. Dharmaratne, N. P. Dhammika Nanayakkara, Ikhlas A. Khan, and Kenneth J. Sufka. 2003. “Anxiolytic Properties of Piper Methysticum Extract Samples and Fractions in the Chick Social-Separation-Stress Procedure.” Phytotherapy Research: PTR 17 (3): 210–16. https://doi.org/10.1002/ptr.1107.

Ferreira, Juliana Veloso, Isabella Campolina Pierotte, Gerson Antônio Pianetti, and Isabela Costa César. 2020. “Simultaneous Quantitation of Kavalactones in Kava Dry Extracts: Comparison of Multi-Standards and Single Standard Validation Approaches.” Phytochemical Analysis: PCA, December. https://doi.org/10.1002/pca.3019.

Flynn, Nicole. 2016. “Comparison of the Anxiolytic Effects of Diazepam and Kava on Behaviour in Rats.” Master of Arts, University of Canterbury. http://ir.canterbury.ac.nz/handle/10092/12806.

Foo, H., and J. Lemon. 1997. “Acute Effects of Kava, Alone or in Combination with Alcohol, on Subjective Measures of Impairment and Intoxication and on Cognitive Performance.” Drug and Alcohol Review 16 (2): 147–55. https://doi.org/10.1080/09595239700186441.

Food and Agriculture Organization of the United Nations, and WHO. 2016. “Kava: A Review of the Safety of Traditional and Recreational Beverage Consumption.”

Food Standards Australia New Zealand. 2004. “KAVA A Human Health Risk Assessment.” 30.

Fragoulis, Athanassios, Stephanie Siegl, Markus Fendt, Sandra Jansen, Ulf Soppa, Lars-Ove Brandenburg, Thomas Pufe, Joachim Weis, and Christoph Jan Wruck. 2017. “Oral Administration of Methysticin Improves Cognitive Deficits in a Mouse Model of Alzheimer’s Disease.” Redox Biology 12 (August): 843–53. https://doi.org/10.1016/j.redox.2017.04.024.

Fu, Dong, and Iqbal Ramzan. 2015. “Use of Kava as a Phytotherapeutic Agent and Kava‐Related Hepatotoxicity.” Phytotherapies, 312–29. https://doi.org/10.1002/9781119006039.ch13.

Fu, Peter P., Qingsu Xia, Lei Guo, Hongtao Yu, and Po-Chuen Chan. 2008. “Toxicity of Kava Kava.” Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews 26 (1): 89–112. https://doi.org/10.1080/10590500801907407.

Fu, Shuang, Anthony Rowe, and Iqbal Ramzan. 2012. “Kavalactone Metabolism in the Isolated Perfused Rat Liver.” Phytotherapy Research: PTR 26 (12): 1813–16. https://doi.org/10.1002/ptr.4656.

Garner, L. F., and J. D. Klinger. 1985. “Some Visual Effects Caused by the Beverage Kava.” Ethnopharmacol. 13 (3): 307–11. https://doi.org/10.1016/0378-8741(85)90076-5.

Gastpar, M., and H. D. Klimm. 2003. “Treatment of Anxiety, Tension and Restlessness States with Kava Special Extract WS 1490 in General Practice: A Randomized Placebo-Controlled Double-Blind Multicenter Trial.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 10 (8): 631–39. https://doi.org/10.1078/0944-7113-00369.

Geier, F. P., and T. Konstantinowicz. 2004. “Kava Treatment in Patients with Anxiety.” Phytotherapy Research: PTR 18 (4): 297–300. https://doi.org/10.1002/ptr.1422.

Gendle, M. H., A. K. Stroman, and D. P. Mullin. 2011. “Effect of an Acute Dose of Crude Kava Root Extract on Problem Solving in Healthy Young Adults.” Australian Journal of Medical Herbalism 23 (4): 160–63. https://search.informit.org/doi/abs/10.3316/informit.858304482995950.

Gerren, Andrew. 2017. “Effects of Varietal Diversity on Knowledge of Kava (Piper Methysticum) in the Pacific.” University of Hawaii at Manoa, May. http://128.171.57.22/handle/10125/56539.

Gleitz, J., A. Beile, P. Wilkens, A. Ameri, and Peters T. 1997. “Gleitz1’ et Al. - 1997 - Antithrombotic Action of the Kava Pyrone ()-Kavain Prepared from Piper Methysticum on Human Platelets.” Planta Medica 63 (1): 27–30. https://doi.org/10.1055/s-2006-957597.

Gow, Paul J., Nathan J. Connelly, Richard L. Hill, Peter Crowley, and Peter W. Angus. 2003. “Fatal Fulminant Hepatic Failure Induced by a Natural Therapy Containing Kava.” The Medical Journal of Australia 178 (9): 442–43. https://doi.org/10.5694/j.1326-5377.2003.tb05286.x.

Grace, Robert F. 2003. “Kava Drinking in Vanuatu--a Hospital Based Survey.” Pacific Health Dialog 10 (2): 41–44. https://www.ncbi.nlm.nih.gov/pubmed/18181414.

Gregory, R. J., J. E. Gregory, and J. G. Peck. 1981. “Kava and Prohibition in Tanna, Vanuatu.” British Journal of Addiction 76 (3): 299–313. https://doi.org/10.1111/j.1360-0443.1981.tb00236.x.

Groth-Marnat, G., S. Leslie, and M. Renneker. 1996. “Tobacco Control in a Traditional Fijian Village: Indigenous Methods of Smoking Cessation and Relapse Prevention.” Social Science & Medicine 43 (4): 473–77. https://doi.org/10.1016/0277-9536(95)00425-4.

Grunze, Heinz, Jens Langosch, Karin Schirrmacher, Dieter Bingmann, Jörg von Wegerer, and Jörg Walden. 2001. “Kava Pyrones Exert Effects on Neuronal Transmission and Transmembraneous Cation Currents Similar to Established Mood Stabilizers - a Review.” Progress in Neuro-Psychopharmacology & Biological Psychiatry 25 (8): 1555–70. https://doi.org/10.1016/S0278-5846(01)00208-1.

Guo, Lei, Qiang Shi, Stacey Dial, Qingsu Xia, Nan Mei, Quan-Zhen Li, Po-Chuen Chan, and Peter Fu. 2010. “Gene Expression Profiling in Male B6C3F1 Mouse Livers Exposed to Kava Identifies--Changes in Drug Metabolizing Genes and Potential Mechanisms Linked to Kava Toxicity.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 48 (2): 686–96. https://doi.org/10.1016/j.fct.2009.11.050.

Gurgel Andrade Pedrosa, Elaine Cristina, Ana Paula Carvalho Bezerra, Ianara Mendonça da Costa, Francisco Irochima Pinheiro, and Fausto Pierdoná Guzen. 2020. “Neuroprotective Profile of Piper Methysticum (Kava Kava) and Its Effects on the Central Nervous System: A Systematic Review.” Journal of Pharmacological Chemistry and Biological Sciences 2 (1): 55–84. https://doi.org/10.36619/jpcbs.2020.2.56.80.

Gurley, Bill J., Ashley Swain, Martha A. Hubbard, D. Keith Williams, Gary Barone, Faith Hartsfield, Yudong Tong, Danielle J. Carrier, Shreekar Cheboyina, and Sunil K. Battu. 2008. “Clinical Assessment of CYP2D6-Mediated Herb-Drug Interactions in Humans: Effects of Milk Thistle, Black Cohosh, Goldenseal, Kava Kava, St. John’s Wort, and Echinacea.” Molecular Nutrition & Food Research 52 (7): 755–63. https://doi.org/10.1002/mnfr.200600300.

H.B. NO. 2494 - ‘Awa; Official State Beverage of Hawaii. 2018. https://www.capitol.hawaii.gov/session2018/bills/HB2494_.HTM.

Hannam, Sarah, Michael Murray, Lucia Romani, Meciusela Tuicakau, and Margot J Whitfeld. 2014. “Kava Dermopathy in Fiji: An Acquired Ichthyosis?” International Journal of Dermatology 53 (12): 1490–94. https://doi.org/10.1111/ijd.12546.

Hegazy, Nada Hany, Hans-Georg Breitinger, and Ulrike Breitinger. 2019. “Kavalactones from Kava (Piper Methysticum) Root Extract as Modulators of Recombinant Human Glycine Receptors.” Biological Chemistry 400 (9): 1205–15. https://doi.org/10.1515/hsz-2019-0112.

Heinze, H. J. 1994. “Pharmacopsychological EfTects ofOxazepam and Kava-Extract in a Visual Search Paradigm Assessed with Event-Related Potentials.” Phannacopsychiat. 27: 224–30.

Hocart, C. H., B. Fankhauser, and D. W. Buckle. 1993. “Chemical Archaeology of Kava, a Potent Brew.” Rapid Communications in Mass Spectrometry: RCM 7 (3): 219–24. https://doi.org/10.1002/rcm.1290070311.

Hong, Nguyen Huu, Tran Dang Xuan, Tsuzuki Eiji, Mitsuhiro Matsuo, and Ogushi Yuichi. 2002. “Evaluation of the Allelopathic Potential of Kava (Piper Methysticum L.) for Weed Control in Rice.” Weed Biology and Management 2 (3): 143–47. https://doi.org/10.1046/j.1445-6664.2002.00062.x.

Hoover, Jason M., Alan D. Kaye, Ikhlass N. Ibrahim, Aaron M. Fields, and Todd A. Richards. 2006. “Analysis of Responses to Kava Kava in the Feline Pulmonary Vascular Bed.” Journal of Medicinal Food 9 (1): 62–71. https://doi.org/10.1089/jmf.2006.9.62.

Hussein, Anan. 2015. “A Closer Look at the Risks vs. Benefits of Kava (Piper Methysticum).” Journal of Student Research 4 (2): 69–72. https://doi.org/10.47611/jsr.v4i2.245.

IARC. 2013. “Kava.” In Some Drugs and Herbal Products, 117–40.

“Increasing Consumer Access to Kava.” n.d. Accessed April 19, 2021. https://www.odc.gov.au/publications/increasing-consumer-access-kava.

Jager, L. S. de, G. A. Perfetti, and G. W. Diachenko. 2004. “LC-UV and LC-MS Analysis of Food and Drink Products Containing Kava.” Food Additives and Contaminants 21 (10): 921–34. https://doi.org/10.1080/02652030400010454.

Jaiswal, Yogini S., Aaron M. Yerke, M. Caleb Bagley, Mans Ekelof, Daniel Weber, Daniel Haddad, Anthony Fodor, David C. Muddiman, and Leonard L. Williams. 2020. “3D Imaging and Metabolomic Profiling Reveal Higher Neuroactive Kavalactone Contents in Lateral Roots and Crown Root Peels of Piper Methysticum (kava).” GigaScience 9 (9). https://doi.org/10.5524/100784.

Jaiswal, Yogini, Mohd Farooq Shaikh, Ilya Wang, Yanning Yong, Vanessa Lin Lin Lee, and Leonard Williams. 2020. “Evaluation of Anti-Convulsive Properties of Aqueous Kava Extract on Zebrafish Using the PTZ-Induced Seizure Model.” Brain Sciences 10 (8). https://doi.org/10.3390/brainsci10080541.

Jandial, Danielle D., Lauren S. Krill, Lixia Chen, Chunli Wu, Yu Ke, Jun Xie, Bang H. Hoang, and Xiaolin Zi. 2017. “Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.” Molecules 22 (3). https://doi.org/10.3390/molecules22030462.

Jayararnan, T. K. 2004. “COPING WITH VULNERABILITY BY BUILDING ECONOMIC RESILIENCE: THE CASE OF VANUATU.” In Economic Vulnerability and Resilience of Small States, 135–48. University of Malta. Islands and Small States Institute & The Commonwealth Secretariat.

Jhoo, J-W, J. P. Freeman, C. Y. W. Ang, and J. J. Mihalov. 2006. “Assessment of Kavalactones in Kava Beverage Products and Aqueous Infusions.” Journal of Food Science 71 (6): C345–51. https://doi.org/10.1111/j.1750-3841.2006.00102.x.

Jhoo, Jin-Woo, James P. Freeman, Thomas M. Heinze, Joanna D. Moody, Laura K. Schnackenberg, Richard D. Beger, Klaus Dragull, Chung-Shih Tang, and Catharina Y. W. Ang. 2006. “In Vitro Cytotoxicity of Nonpolar Constituents from Different Parts of Kava Plant (Piper Methysticum).” Journal of Agricultural and Food Chemistry 54 (8): 3157–62. https://doi.org/10.1021/jf051853j.

Johana, A. Mendes, Y. Ekowati Nurhening, S. Susanti Diana, Sembiring Jefri, Prasetia Andri, and Widijastuti Rosmala. 2018. “The Potential Leaves Extract of Piper Methysticum (piperaceae) as Botanical Insecticide against Crocidolomia Pavonana (f.) Larvae Mortality (lepidoptera:crambidae).” E3S Web of Conferences 73: 06015. https://doi.org/10.1051/e3sconf/20187306015.

Johnson, Benjamin M., Sheng-Xiang Qiu, Shide Zhang, Fagen Zhang, Joanna E. Burdette, Linning Yu, Judy L. Bolton, and Richard B. van Breemen. 2003. “Identification of Novel Electrophilic Metabolites of Piper Methysticum Forst (Kava).” Chemical Research in Toxicology 16 (6): 733–40. https://doi.org/10.1021/tx020113r.

Johnson, Thomas E., David Hermanson, Lei Wang, Fekadu Kassie, Pramod Upadhyaya, Michael G. O’Sullivan, Stephen S. Hecht, Junxuan Lu, and Chengguo Xing. 2011. “Lung Tumorigenesis Suppressing Effects of a Commercial Kava Extract and Its Selected Compounds in A/J Mice.” The American Journal of Chinese Medicine 39 (4): 727–42. https://doi.org/10.1142/S0192415X11009202.

Johnson, Thomas E., Fekadu Kassie, M. Gerard O’Sullivan, Mesfin Negia, Timothy E. Hanson, Pramod Upadhyaya, Peter P. Ruvolo, Stephen S. Hecht, and Chengguo Xing. 2008. “Chemopreventive Effect of Kava on 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone plus Benzo[a]pyrene–Induced Lung Tumorigenesis in A/J Mice.” Cancer Prevention Research 1 (6): 430–38. https://doi.org/10.1158/1940-6207.CAPR-08-0027.

Jokhan, Anjeela D., and Patricia A. McLenachan. 2004. “Genetic Fingerprinting of Fijian Kava.” The South Pacific Journal of Natural and Applied Sciences 22 (1): 43–45. https://doi.org/10.1071/sp04008.

Jussofie, A., A. Schmiz, and C. Hiemke. 1994. “Kavapyrone Enriched Extract from Piper Methysticum as Modulator of the GABA Binding Site in Different Regions of Rat Brain.” Psychopharmacology 116 (4): 469–74. https://doi.org/10.1007/BF02247480.

Kandukuru, P., A. S. Huang, J. Dong, H. C. Bittenbender, and Y. Li. 2009. “Rapid Identification of Bacterial Isolates from Aqueous Kava (Piper Methysticum) Extracts by Polymerase Chain Reaction and DNA Sequencing.” Letters in Applied Microbiology 49 (6): 764–68. https://doi.org/10.1111/j.1472-765X.2009.02739.x.

Kautu, Bwarenaba B., Juliana Phillips, Kellie Steele, M. Shawn Mengarelli, and Eric A. Nord. 2017. “A Behavioral Survey of the Effects of Kavalactones on Caenorhabditis Elegans Neuromuscular Transmission.” Journal of Experimental Neuroscience 11 (June): 1179069517705384. https://doi.org/10.1177/1179069517705384.

“Kava.” n.d. Accessed May 5, 2021. https://www.betterhealth.vic.gov.au/health/healthyliving/kava.

Keledjian, J., P. H. Duffield, D. D. Jamieson, R. O. Lidgard, and A. M. Duffield. 1988. “Uptake into Mouse Brain of Four Compounds Present in the Psychoactive Beverage Kava.” Journal of Pharmaceutical Sciences 77 (12): 1003–6. https://doi.org/10.1002/jps.2600771203.

Ketola, Raimo A., Jenni Viinamäki, Ilpo Rasanen, Anna Pelander, and Sirkka Goebeler. 2015. “Fatal Kavalactone Intoxication by Suicidal Intravenous Injection.” Forensic Science International 249 (April): e7–11. https://doi.org/10.1016/j.forsciint.2015.01.032.

Klaus Dragull Jim Henderson Mel C. Jackson Ed Johnston Jerry Konanui G. David Lin Kepā Maly Scot Nelson Jeri Ooka Tom Osborn Helen Rogers Chung-Shih Tang. 2006. Hawaiian ‘Awa Views of an Ethnobotanical Treasure. Edited by Ed Johnston and Helen Rogers. Association for Hawaiian ‘Awa.

Klohs, M. W., Keller, F., Williams, R. E., Toekes, M. I., Cronheim, G. E. 1959. “A Chemical and Pharmacological Investigation of Piper Methysticum Forst.” Journal of Medicinal and Pharmaceutical Chemistry 1 (1): 95–103. https://doi.org/10.1021/jm50002a007.

Kong, Yulong, Xiaoguang Gao, Changyuan Wang, Chenqing Ning, Kexin Liu, Zhihao Liu, Huijun Sun, Xiaodong Ma, Pengyuan Sun, and Qiang Meng. 2018. “Protective Effects of Yangonin from an Edible Botanical Kava against Lithocholic Acid-Induced Cholestasis and Hepatotoxicity.” European Journal of Pharmacology 824 (April): 64–71. https://doi.org/10.1016/j.ejphar.2018.02.002.

Krum, Bárbara Nunes, Catiuscia Molz de Freitas, Ana Paula Chiapinotto Ceretta, Caroline Pilecco Barbosa, Elizete de Moraes Reis, Rahisa Scussel, Emily da Silva Córneo, Ricardo Andrez Machado-de-Ávila, Aline Augusti Boligon, and Roselei Fachinetto. 2021. “Kava Decreases the Stereotyped Behavior Induced by Amphetamine in Mice.” Journal of Ethnopharmacology 265 (January): 113293. https://doi.org/10.1016/j.jep.2020.113293.

Kubátová, A., D. J. Miller, and S. B. Hawthorne. 2001. “Comparison of Subcritical Water and Organic Solvents for Extracting Kava Lactones from Kava Root.” Journal of Chromatography. A 923 (1-2): 187–94. https://doi.org/10.1016/s0021-9673(01)00979-7.

Kuchta, Kenny, Marie Hladikova, Michael Thomsen, Adolf Nahrstedt, and Mathias Schmidt. 2021. “Kava (Piper Methysticum) Extract for the Treatment of Nervous Anxiety, Tension and Restlessness.” Drug Research 71 (2): 83–93. https://doi.org/10.1055/a-1268-7135.

Kuchta, Kenny, Pietro de Nicola, and Mathias Schmidt. 2018. “Randomized, Dose-Controlled Double-Blind Trial: Efficacy of an Ethanolic Kava (Piper Methysticum Rhizome) Extract for the Treatment of Anxiety in Elderly Patients: Kava Extract for Anxiety.” Traditional & Kampo Medicine 5 (1): 3–10. https://doi.org/10.1002/tkm2.1079.

Kuchta, Kenny, Mathias Schmidt, and Adolf Nahrstedt. 2015. “German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper Methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics.” Planta Medica 81 (18): 1647–53. https://doi.org/10.1055/s-0035-1558295.

Kumagai, Momochika, Keisuke Nishikawa, Takashi Mishima, Izumi Yoshida, Masahiro Ide, Akio Watanabe, Kazuhiro Fujita, and Yoshiki Morimoto. 2020. “Fluorinated Kavalactone Inhibited RANKL-Induced Osteoclast Differentiation of RAW264 Cells.” Biological & Pharmaceutical Bulletin 43 (5): 898–903. https://doi.org/10.1248/bpb.b20-00063.

LaPorte, E., J. Sarris, C. Stough, and A. Scholey. 2011. “Neurocognitive Effects of Kava (Piper Methysticum): A Systematic Review.” Human Psychopharmacology 26 (2): 102–11. https://doi.org/10.1002/hup.1180.

Lasme, Privat, Fabrice Davrieux, Didier Montet, and Vincent Lebot. 2008. “Quantification of Kavalactones and Determination of Kava (Piper Methysticum) Chemotypes Using near-Infrared Reflectance Spectroscopy for Quality Control in Vanuatu.” Journal of Agricultural and Food Chemistry 56 (13): 4976–81. https://doi.org/10.1021/jf800439g.

Lebot, V. 1996. “Evidence for Conspecificity of Piper Methysticum Forst. F. and Piper Wichmannii C. DC.” Biochemical Systematics and Ecology. https://doi.org/10.1016/s0305-1978(97)81216-1.

Lebot, V., T. K. T. Do, and L. Legendre. 2014. “Detection of Flavokavins (A, B, C) in Cultivars of Kava (Piper Methysticum) Using High Performance Thin Layer Chromatography (HPTLC).” Food Chemistry 151 (May): 554–60. https://doi.org/10.1016/j.foodchem.2013.11.120.

Lebot, Vincent. 1995. “The Origin And Distribution Of Kava.” Canberra Anthropology 18 (1-2): 20–33. https://doi.org/10.1080/03149099509508407.

Lebot, Vincent, z. Mallikarjuna K. Aradhya, and Richard M. Manshardt. 1991. “Geographic Survey of Genetic Variation in Kava (Piper Methysticum Forst. F. and P. Wichmannii C. DC.).” Pacific Science 45 (2): 169–85. http://hdl.handle.net/10125/518.

Lebot Vincent, Cabalion Pierre. 1988. KAVAS OF VANUATU Cultivars of Piper Methysticum Forst. South Pacific Commission Technical Paper.

Lebot, Vincent, Juliane Kaoh, and Laurent Legendre. 2020. “High-Throughput Analysis of Flavokawains in Kava (Piper Methysticum Forst. F.) Roots, Chips and Powders and Correlations with Their Acetonic Extracts Absorbance.” Food Analytical Methods 13 (8): 1583–93. https://doi.org/10.1007/s12161-020-01781-9.

Lebot, Vincent, and Laurent Legendre. 2016. “Comparison of Kava (Piper Methysticum Forst.) Varieties by UV Absorbance of Acetonic Extracts and High-Performance Thin-Layer Chromatography.” Journal of Food Composition and Analysis: An Official Publication of the United Nations University, International Network of Food Data Systems 48 (May): 25–33. https://doi.org/10.1016/j.jfca.2016.01.009.

Lebot, Vincent, and Joël Levesque. 1996. “Genetic Control of Kavalactone Chemotypes in Piper Methysticum Cultivars.” Phytochemistry 43 (2): 397–403. https://doi.org/10.1016/0031-9422(96)00209-9.

Lebot, Vincent, Dennis J. McKenna, Ed Johnston, Qun Yi Zheng, and Doug McKern. 1999. “Morphological, Phytochemical, and Genetic Variation in Hawaiian Cultivars of ’Awa (Kava,Piper Methysticum, Piperaceae).” Economic Botany 53 (4): 407–18. https://doi.org/10.1007/bf02866720.

Lebot, Vincent, Serge Michalet, and Laurent Legendre. 2019. “Kavalactones and Flavokavins Profiles Contribute to Quality Assessment of Kava (Piper Methysticum G. Forst.), the Traditional Beverage of the Pacific.” Beverages 5 (2): 34. https://doi.org/10.3390/beverages5020034.

Lebot, Vincent, and Patricia Siméoni. 2004. “Is the Quality of Kava (Piper Methysticum Forst. F.) Responsible for Different Geographical Patterns?” Ethnobotany Research and Applications. https://scholarspace.manoa.hawaii.edu/handle/10125/135.

Lehrl, Siegfried. 2004. “Clinical Efficacy of Kava Extract WS 1490 in Sleep Disturbances Associated with Anxiety Disorders. Results of a Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial.” Journal of Affective Disorders 78 (2): 101–10. https://doi.org/10.1016/s0165-0327(02)00238-0.

Lemert, E. M. 1967. “Secular Use of Kava in Tonga.” Quarterly Journal of Studies on Alcohol 28 (2): 328–41. https://www.ncbi.nlm.nih.gov/pubmed/6049173.

Lester, R. H. 1941. “Kava Drinking in Vitilevu, Fiji.” Oceania; a Journal Devoted to the Study of the Native Peoples of Australia, New Guinea, and the Islands of the Pacific 12 (2): 97–121. http://www.jstor.org/stable/40327938.

Lhuissier, Tiphaine, Pierre-Edouard Mercier, Serge Michalet, Vincent Lebot, and Laurent Legendre. 2017. “Colorimetric Assessment of Kava (Piper Methysticum Forst.) Quality.” Journal of Food Composition and Analysis: An Official Publication of the United Nations University, International Network of Food Data Systems 59 (June): 27–34. https://doi.org/10.1016/j.jfca.2017.02.005.

Li, Juan, Lei Zheng, Mi Yan, Jing Wu, Yongqing Liu, Xiaona Tian, Wen Jiang, Lu Zhang, and Rongmei Wang. 2020. “Activity and Mechanism of Flavokawain A in Inhibiting P-Glycoprotein Expression in Paclitaxel Resistance of Lung Cancer.” Oncology Letters 19 (1): 379–87. https://doi.org/10.3892/ol.2019.11069.

Li, Xuesen, Zhongbo Liu, Xia Xu, Christopher A. Blair, Zheng Sun, Jun Xie, Michael B. Lilly, and Xiaolin Zi. 2012. “Kava Components down-Regulate Expression of AR and AR Splice Variants and Reduce Growth in Patient-Derived Prostate Cancer Xenografts in Mice.” PloS One 7 (2): e31213. https://doi.org/10.1371/journal.pone.0031213.

Li, Xuesen, Xia Xu, Tao Ji, Zhongbo Liu, Mai Gu, Bang H. Hoang, and Xiaolin Zi. 2014. “Dietary Feeding of Flavokawain A, a Kava Chalcone, Exhibits a Satisfactory Safety Profile and Its Association with Enhancement of Phase II Enzymes in Mice.” Toxicology Reports 1: 2–11. https://doi.org/10.1016/j.toxrep.2014.02.002.

Li, Xuesen, Noriko N. Yokoyama, Saiyang Zhang, Lina Ding, Hong-Min Liu, Michael B. Lilly, Dan Mercola, and Xiaolin Zi. 2015. “Flavokawain A Induces deNEDDylation and Skp2 Degradation Leading to Inhibition of Tumorigenesis and Cancer Progression in the TRAMP Transgenic Mouse Model.” Oncotarget 6 (39): 41809–24. https://doi.org/10.18632/oncotarget.6166.

Li, Yan, Hu Mei, Qiangen Wu, Suhui Zhang, Jia-Long Fang, Leming Shi, and Lei Guo. 2011. “Methysticin and 7,8-Dihydromethysticin Are Two Major Kavalactones in Kava Extract to Induce CYP1A1.” Toxicological Sciences: An Official Journal of the Society of Toxicology 124 (2): 388–99. https://doi.org/10.1093/toxsci/kfr235.

Ligresti, Alessia, Rosaria Villano, Marco Allarà, István Ujváry, and Vincenzo Di Marzo. 2012. “Kavalactones and the Endocannabinoid System: The Plant-Derived Yangonin Is a Novel CB₁ Receptor Ligand.” Pharmacological Research: The Official Journal of the Italian Pharmacological Society 66 (2): 163–69. https://doi.org/10.1016/j.phrs.2012.04.003.

Lim, Steven T. S., Klaus Dragull, Chung-Shih Tang, Harry C. Bittenbender, Jimmy T. Efird, and Pratibha V. Nerurkar. 2007. “Effects of Kava Alkaloid, Pipermethystine, and Kavalactones on Oxidative Stress and Cytochrome P450 in F-344 Rats.” Toxicological Sciences: An Official Journal of the Society of Toxicology 97 (1): 214–21. https://doi.org/10.1093/toxsci/kfm035.

Lin, Chien-Tsong, K. Jayabal Senthil Kumar, Yen-Hsueh Tseng, Zi-Jie Wang, Mu-Yun Pan, Jun-Hong Xiao, Shih-Chang Chien, and Sheng-Yang Wang. 2009. “Anti-Inflammatory Activity of Flavokawain B from Alpinia Pricei Hayata.” Journal of Agricultural and Food Chemistry 57 (14): 6060–65. https://doi.org/10.1021/jf900517d.

Lindstrom, Lamont. 2009. “Kava Pirates in Vanuatu?” International Journal of Cultural Property 16 (03): 291–308. https://doi.org/10.1017/S0940739109990208.

Liu, Ying, Jensen A. Lund, Susan J. Murch, and Paula N. Brown. 2018. “Single-Lab Validation for Determination of Kavalactones and Flavokavains in Piper Methysticum (Kava).” Planta Medica 84 (16): 1213–18. https://doi.org/10.1055/a-0637-2400.
 
Last edited:

Kapmcrunk

The Kaptain (40g)
KavaForums Founder
2nd Half of the list.

Liu, Zhongbo, Xia Xu, Xuesen Li, Shuman Liu, Anne R. Simoneau, Feng He, Xue-Ru Wu, and Xiaolin Zi. 2013. “Kava Chalcone, Flavokawain A, Inhibits Urothelial Tumorigenesis in the UPII-SV40T Transgenic Mouse Model.” Cancer Prevention Research 6 (12): 1365–75. https://doi.org/10.1158/1940-6207.CAPR-13-0219.

Lopez-Avila, Viorica, and Janet Benedicto. 1997. “Supercritical Fluid Extraction of Kava Lactones from Piper Methysticum (Kava) Herb.” Journal of High Resolution Chromatography 20: 555–59. https://doi.org/10.1002/jhrc.1240201007.

Lopez-Avila, Viorica, and George Yefchak. 2009. “Identification of Compounds in Commercial Kava Extracts by Gas Chromatography with Electron Ionization High-Resolution Mass Spectrometry.” The Open Analytical Chemistry Journal 3 (1): 22–31. https://doi.org/10.2174/1874065000903010022.

Lüde, Saskia, Michael Török, Sandy Dieterle, René Jäggi, Karin Berger Büter, and Stephan Krähenbühl. 2008. “Hepatocellular Toxicity of Kava Leaf and Root Extracts.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 15 (1-2): 120–31. https://doi.org/10.1016/j.phymed.2007.11.003.

Luders, David. 1996. “LEGEND AND HISTORY: DID THE VANUATU-TONGA KAVA TRADE CEASE IN A.D. 1447?” The Journal of the Polynesian Society. Polynesian Society 105 (3): 287–310. http://www.jstor.org/stable/20706669.

Lynch, John. 1996. “KAVA-DRINKING IN SOUTHERN VANUATU: MELANESIAN DRINKERS, POLYNESIAN ROOTS.” The Journal of the Polynesian Society. Polynesian Society 105 (1): 27–40. http://www.jstor.org/stable/20706644.

———. 2002. “Potent Roots and the Origin of Kava.” Oceanic Linguistics 41 (2): 493–513. https://doi.org/10.2307/3623318.

Ma, Yuzhong, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester, and Bingfang Yan. 2004. “Desmethoxyyangonin and Dihydromethysticin Are Two Major Pharmacological Kavalactones with Marked Activity on the Induction of CYP3A23.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 32 (11): 1317–24. https://doi.org/10.1124/dmd.104.000786.

Madhavaram, H., T. Patel, and C. Kyle. 2020. “Kavain Interference with Amphetamine Immunoassay.” Journal of Analytical Toxicology, December. https://doi.org/10.1093/jat/bkaa178.

Magura, E. I., M. V. Kopanitsa, J. Gleitz, T. Peters, and O. A. Krishtal. 1997. “Kava Extract Ingredients, ( )-Methysticin and (±)-Kavain Inhibit Voltage-Operated Na -Channels in Rat CA1 Hippocampal Neurons.” Neuroscience. https://doi.org/10.1016/s0306-4522(97)00177-2.

Malsch, U., and M. Kieser. 2001. “Efficacy of Kava-Kava in the Treatment of Non-Psychotic Anxiety, Following Pretreatment with Benzodiazepines.” Psychopharmacology 157 (3): 277–83. https://doi.org/10.1007/s002130100792.

Maneze, Della, Anau Speizer, Noeline Dalton, and Sarah Dennis. 2008. “A Descriptive Study of Kava Use among Tongan Men in Macarthur, Sydney South West.” Australian and New Zealand Journal of Public Health 32 (4): 314–16. https://doi.org/10.1111/j.1753-6405.2008.00246.x.

Martin, Amanda C., Ed Johnston, Chengguo Xing, and Adrian D. Hegeman. 2014. “Measuring the Chemical and Cytotoxic Variability of Commercially Available Kava (Piper Methysticum G. Forster).” PloS One 9 (11): e111572. https://doi.org/10.1371/journal.pone.0111572.

Mathews, J. D., M. D. Riley, L. Fejo, E. Munoz, N. R. Milns, I. D. Gardner, J. R. Powers, E. Ganygulpa, and B. J. Gununuwawuy. 1988. “Effects of the Heavy Usage of Kava on Physical Health: Summary of a Pilot Survey in an Aboriginal Community.” The Medical Journal of Australia 148 (11): 548–55. https://doi.org/10.5694/j.1326-5377.1988.tb93809.x.

Mathews, James M., Amy S. Etheridge, John L. Valentine, Sherry R. Black, Donna P. Coleman, Purvi Patel, James So, and Leo T. Burka. 2005. “Pharmacokinetics and Disposition of the Kavalactone Kawain: Interaction with Kava Extract and Kavalactones in Vivo and in Vitro.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 33 (10): 1555–63. https://doi.org/10.1124/dmd.105.004317.

Mcdonald, David, and Anit A. Jowit T. 2000. “Kava in the Pacific Islands: A Contemporary Drug of Abuse?” Drug and Alcohol Revie W 19: 217.

Meseguer, Elena, Rocio Taboada, Vicenta Sánchez, María Angeles Mena, Victor Campos, and Justo García De Yébenes. 2002. “Life-Threatening Parkinsonism Induced by Kava-Kava.” Movement Disorders: Official Journal of the Movement Disorder Society 17 (1): 195–96. https://doi.org/10.1002/mds.1268.

Meyer, H. J. 1965. “Antagonistic Effects of Genuine Kawa-Pyrons in Experimental Inflammation and Fever.” Klinische Wochenschrift 43: 469–70. https://doi.org/10.1007/BF01483859.

Mikell, J. R., B. T. Schaneberg, and I. A. Khan. 2003. “Isolation and Purification of Kava Lactones by High Performance Centrifugal Partition Chromatography.” Journal of Liquid Chromatography & Related Technologies 26 (18): 3069–74. https://doi.org/10.1081/JLC-120025423.

Mohanty, Manoranjan. 2017. “Fiji Kava: Production, Trade, Role and Challenges.” The Journal of Pacific Studies 37 (1): 5–30.

Moulds, Robert F. W., and Joji Malani. 2003. “Kava: Herbal Panacea or Liver Poison?” The Medical Journal of Australia 178 (9): 451–53. https://doi.org/10.5694/j.1326-5377.2003.tb05289.x.

Mückler, Hermann. 2013. “Chiefs, Coups and Kava: Conflicts and Conflict Resolution in Fiji.” http://www.hermann-mueckler.com/pdf/Communi+Conflict.pdf.

Mulholland, Patrick J., and Mark A. Prendergast. 2002. “Post-Insult Exposure to (+/-) Kavain Potentiates N-Methyl-D-Aspartate Toxicity in the Developing Hippocampus.” Brain Research 945 (1): 106–13. https://doi.org/10.1016/s0006-8993(02)02745-2.

Münte TF, Heinze HJ, Matzke M, Steitz J. 1993. “Effects of Oxazepam and an Extract of Kava Roots (Piper Methysticum) on Event-Related Potentials in a Word Recognition Task.” Neuropsychobiology 27 (1): 46–53. https://doi.org/10.1159/000118952.

Murray, Michael. 2012. “Toxicological Actions of Plant-Derived and Anthropogenic Methylenedioxyphenyl-Substituted Chemicals in Mammals and Insects.” Journal of Toxicology and Environmental Health. Part B, Critical Reviews 15 (6): 365–95. https://doi.org/10.1080/10937404.2012.705105.

Musselmann B & Cappellaro. 2015. “Kava Kava.” Zeitschrift Für Komplementärmedizin 07 (03): 44–45. https://doi.org/10.1055/s-0035-1554957.

Narayanapillai, Sreekanth C., Silvia Balbo, Pablo Leitzman, Alex E. Grill, Pramod Upadhyaya, Ahmad Ali Shaik, Bo Zhou, et al. 2014. “Dihydromethysticin from Kava Blocks Tobacco Carcinogen 4-(methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced Lung Tumorigenesis and Differentially Reduces DNA Damage in A/J Mice.” Carcinogenesis 35 (10): 2365–72. https://doi.org/10.1093/carcin/bgu149.

Narayanapillai, Sreekanth C., Pablo Leitzman, M. Gerard O’Sullivan, and Chengguo Xing. 2014. “Flavokawains a and B in Kava, Not Dihydromethysticin, Potentiate Acetaminophen-Induced Hepatotoxicity in C57BL/6 Mice.” Chemical Research in Toxicology 27 (10): 1871–76. https://doi.org/10.1021/tx5003194.

National Institute of Health. 2018. “Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Kava Kava.” In LiverTox: Clinical and Research Information on Drug- Induced Liver Injury. NIH.

Ngirasowei, J., and J. Malani. 1998. “The Relationship between Sakau (kava) and Gastritis.” Pacific Health Dialog 5 (2): 266–67. http://pacifichealthdialog.org.fj/V...cations/The20relationship20between20Sakau.pdf.

Noor, Neveen A. 2010. “Anxiolytic Action and Safety of Kava: Effect on Rat Brain Acetylcholinesterase Activity and Some Serum Biochemical Parameters.” African Journal of Pharmacy and Pharmacology 4 (11): 823–28. http://dx.doi.org/.

Northern Territory Government. 2020. “Penalty Units.” Northern Territory Government. June 22, 2020. https://justice.nt.gov.au/attorney-general-and-justice/units-and-amounts/penalty-units.

Norton, S. A., and P. Ruze. 1994. “Kava Dermopathy.” Journal of the American Academy of Dermatology 31 (1): 89–97. https://doi.org/10.1016/s0190-9622(94)70142-3.

Nosa, Vili, and Malakai Ofanoa. 2009. “The Social, Cultural and Medicinal Use of Kava for Twelve Tongan Born Men Living in Auckland, New Zealand.” Pacific Health Dialog 15 (1): 96–102. https://www.ncbi.nlm.nih.gov/pubmed/19585739.

O’hara, Maureen J., William J. Kinnard, and Joseph P. Buckley. 1965. “Preliminary Characterization of Aqueous Extracts of Piper Methysticum (Kava, Kawa Kawa).” J Pharm Sci. 54 (7): 1021–25. https://doi.org/10.1002/jps.2600540715.

Ofanoa, Malakai, Stephen Buetow, Samuela Ofanoa, Peter Huggard, Janine Paynter, and Vili Nosa. 2020. “Reasons for and Impacts of Kava Use by Tongan Men in Kava Clubs in Auckland and Tonga.” Social Sciences 9 (2): 56–60. https://pdfs.semanticscholar.org/17e2/4e08a5f53d273c78660f5181125db790e8ab.pdf.

Olsen, Line R., Mark P. Grillo, and Christian Skonberg. 2011. “Constituents in Kava Extracts Potentially Involved in Hepatotoxicity: A Review.” Chemical Research in Toxicology 24 (7): 992–1002. https://doi.org/10.1021/tx100412m.

Ooi, Soo Liang, Penny Henderson, and Sok Cheon Pak. 2018. “Kava for Generalized Anxiety Disorder: A Review of Current Evidence.” Journal of Alternative and Complementary Medicine 24 (8): 770–80. https://doi.org/10.1089/acm.2018.0001.

Pantano, Flaminia, Roberta Tittarelli, Giulio Mannocchi, Simona Zaami, Serafino Ricci, Raffaele Giorgetti, Daniela Terranova, Francesco P. Busardò, and Enrico Marinelli. 2016. “Hepatotoxicity Induced by ‘the 3Ks’: Kava, Kratom and Khat.” International Journal of Molecular Sciences 17 (4): 580. https://doi.org/10.3390/ijms17040580.

Perez, Juan, and James F. Holmes. 2005. “Altered Mental Status and Ataxia Secondary to Acute Kava Ingestion.” The Journal of Emergency Medicine 28 (1): 49–51. https://doi.org/10.1016/j.jemermed.2004.10.003.

Pescitelli, G., A. R. Bilia, M. C. Bergonzi, F. F. Vincieri, and L. Di Bari. 2010. “Cyclodextrins as Carriers for Kavalactones in Aqueous Media: Spectroscopic Characterization of (S)-7,8-Dihydrokavain and Beta-Cyclodextrin Inclusion Complex.” Journal of Pharmaceutical and Biomedical Analysis 52 (4): 479–83. https://doi.org/10.1016/j.jpba.2010.01.037.

Peterman, Kaeleigh, and Emily Reynolds. 2019. “Kava-Induced Ichthyosis.” Journal of the Dermatology Nurses’ Association 11 (6): 280. https://doi.org/10.1097/JDN.0000000000000503.

Petersen, Glenn. 1995. “The Complexity of Power, the Subtlety of Kava.” Canberra Anthropology 18 (1-2): 34–60. https://doi.org/10.1080/03149099509508408.

Petersen, Greg E., Yijin Tang, and Christine Fields. 2019. “Chemical and in Vitro Toxicity Analysis of a Supercritical Fluid Extract of Kava Kava (Piper Methysticum).” Journal of Ethnopharmacology 235 (May): 301–8. https://doi.org/10.1016/j.jep.2019.01.032.

PHAMA. 2018. FIJI KAVA VALUE CHAIN ANALYSIS. Australian Government and New Zealand Government.

Philibert, Jean-Marc. 2010. “The Politics of Tradition: Toward a Generic Culture in Vanuatu.” Mankind 16 (1): 1–12. https://doi.org/10.1111/j.1835-9310.1986.tb01274.x.

Pinner, Keanu D., Christina T. K. Wales, Rachel A. Gristock, Hoa T. Vo, Nadine So, and Aaron T. Jacobs. 2016. “Flavokawains A and B from Kava (Piper Methysticum) Activate Heat Shock and Antioxidant Responses and Protect against Hydrogen Peroxide-Induced Cell Death in HepG2 Hepatocytes.” Pharmaceutical Biology 54 (9): 1503–12. https://doi.org/10.3109/13880209.2015.1107104.

Pittler, M. H., and E. Ernst. 2003. “Kava Extract versus Placebo for Treating Anxiety.” Cochrane Database of Systematic Reviews, no. 1. https://doi.org/10.1002/14651858.CD003383.

Pluskal, Tomáš, Michael P. Torrens-Spence, Timothy R. Fallon, Andrea De Abreu, Cindy H. Shi, and Jing-Ke Weng. 2019. “The Biosynthetic Origin of Psychoactive Kavalactones in Kava.” Nature Plants 5 (8): 867–78. https://doi.org/10.1038/s41477-019-0474-0.

Pollastri, Michael P., Adrian Whitty, Jamie Cassidy Merrill, Xiaoren Tang, Trent D. Ashton, and Salomon Amar. 2009. “Identification and Characterization of Kava-Derived Compounds Mediating TNF-Alpha Suppression.” Chemical Biology & Drug Design 74 (2): 121–28. https://doi.org/10.1111/j.1747-0285.2009.00838.x.

Pollock, Nancy J. 1991. “The Abandoned Narcotic: Kava and Cultural Instability in Melanesia. Ron Brunton, Jack Goody.” American Anthropologist 93 (4): 1024–25. https://doi.org/10.1525/aa.1991.93.4.02a00910.

———. 1995. “The Power of Kava.” Canberra Anthropology 18 (1-2): 1–19. https://doi.org/10.1080/03149099509508406.

———. 2009. “Sustainability of the Kava Trade.” The Contemporary Pacific 21 (2): 265–97. https://doi.org/10.1353/cp.0.0070.

Prasad, Naren, and Shiu Raj. 2006. “The Perils of Unmanaged Export Growth: The Case of Kava in Fiji.” International Journal of Entrepreneurship & Small Business 19 (4): 381–93. https://doi.org/10.1080/08276331.2006.10593378.

Prescott, J. 1990. “Kava Use in Australia.” Drug and Alcohol Review 9 (4): 325–28. https://doi.org/10.1080/09595239000185451.

Prinsloo, Denise, Sandra van Dyk, Anél Petzer, and Jacobus P. Petzer. 2019. “Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum).” Planta Medica 85 (14-15): 1136–42. https://doi.org/10.1055/a-1008-9491.

Puppala M, Narayanapillai SC, Leitzman P, Sun H, Upadhyaya P, O’Sullivan MG, Hecht SS, Xing C. 2017. “Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced O 6-Methylguanine and Lung Tumor in A/J Mice.” Journal of Medicinal Chemistry 28 (60): 7935–40. https://doi.org/10.1021/acs.jmedchem.7b00921.

R. I. Davis, J. F. Brown. 1999. “Kava (Piper Methysticum) in the South Pacific: Its Importance, Methods of Cultivation, Cultivars, Diseases and Pests.” Australian Centre for International Agricultural Research.

Raduege, Kevin M., James F. Kleshinski, J. Victor Ryckman, and John E. Tetzlaff. 2004. “Anesthetic Considerations of the Herbal, Kava.” Journal of Clinical Anesthesia 16 (4): 305–11. https://doi.org/10.1016/j.jclinane.2003.08.009.

“REPORT ON KAVA ANALYSIS 2012-2015 (JULY).” n.d. Accessed May 3, 2021. https://brusselsbriefings.files.wordpress.com/2016/05/report-on-kava-analysis-2012-2015.pdf.

Rivers, Z., C. Xing, and Sjmc Narayanapillai. 2016. “Kava as a Pharmacotherapy of Anxiety Disorders: Promises and Concerns.” Medicinal Chemistry 6: 81–87.

Robinson, Daniel, Margaret Raven, Elizabeth Makin, Donna Kalfatak, Francis Hickey, and Trinison Tari. 2021. “Legal Geographies of Kava, Kastom and Indigenous Knowledge: Next Steps under the Nagoya Protocol.” Geoforum; Journal of Physical, Human, and Regional Geosciences 118 (January): 169–79. https://doi.org/10.1016/j.geoforum.2020.11.001.

Robinson, Valerie, Wilma F. Bergfeld, Donald V. Belsito, Curtis D. Klaassen, James G. Marks, Ronald C. Shank, Thomas J. Slaga, Paul W. Snyder, and F. Alan Andersen. 2009. “Final Report on the Safety Assessment of Piper Methysticum Leaf/Root/Stem Extract and Piper Methysticum Root Extract.” International Journal of Toxicology. https://doi.org/10.1177/10915818093509341.

Rowe, A., R. Narlawar, P. W. Groundwater, and I. Ramzan. 2011. “Kavalactone Pharmacophores for Major Cellular Drug Targets.” Mini Reviews in Medicinal Chemistry 11 (1): 79–83. https://doi.org/10.2174/138955711793564088.

Rowe, Anthony, Lillian Yuan Zhang, and Iqbal Ramzan. 2011. “Toxicokinetics of Kava.” Advances in Pharmacological Sciences 2011 (March): 326724. https://doi.org/10.1155/2011/326724.

Russmann, Stefan, Yann Barguil, Pierre Cabalion, Marina Kritsanida, Daniel Duhet, and Bernhard H. Lauterburg. 2003. “Hepatic Injury due to Traditional Aqueous Extracts of Kava Root in New Caledonia.” European Journal of Gastroenterology & Hepatology 15: 1033–36. https://doi.org/10.1097/01.meg.0000085464.12407.7b.

Ruze, P. 1990. “Kava-Induced Dermopathy: A Niacin Deficiency?” The Lancet 335 (8703): 1442–45. https://doi.org/10.1016/0140-6736(90)91458-m.

Rychetnik, Lucie, and Christine M. Madronio. 2011. “The Health and Social Effects of Drinking Water-Based Infusions of Kava: A Review of the Evidence.” Drug and Alcohol Review 30 (1): 74–83. https://doi.org/10.1111/j.1465-3362.2010.00184.x.

Saeed, S. Y. Atezaz, Richard M. Bloch, and Diana J. Antonacci. 2007. “Herbal and Dietary Supplements for Treatment of Anxiety Disorders.” Am Fam Physician 15 (76): 549–56. https://www.aafp.org/afp/2007/0815/p549.html.

Saroya, Amritpal Singh, and Jaswinder Singh. 2018. “Piper Methysticum G.Forst: A Potent Antianxiety Agent.” In Pharmacotherapeutic Potential of Natural Products in Neurological Disorders, 95–106. Springer, Singapore. https://doi.org/10.1007/978-981-13-0289-3_7.

Sarris, J., D. J. Kavanagh, G. Byrne, K. M. Bone, J. Adams, and G. Deed. 2009. “The Kava Anxiety Depression Spectrum Study (KADSS): A Randomized, Placebo-Controlled Crossover Trial Using an Aqueous Extract of Piper Methysticum.” Psychopharmacology 205 (3): 399–407. https://doi.org/10.1007/s00213-009-1549-9.

Sarris, J., E. Laporte, A. Scholey, R. King, A. Pipingas, I. Schweitzer, and C. Stough. 2013. “Does a Medicinal Dose of Kava Impair Driving? A Randomized, Placebo-Controlled, Double-Blind Study.” Traffic Injury Prevention 14 (1): 13–17. https://doi.org/10.1080/15389588.2012.682233.

Sarris, J., C. Stough, R. Teschke, Z. T. Wahid, C. A. Bousman, G. Murray, K. M. Savage, P. Mouatt, C. Ng, and I. Schweitzer. 2013. “Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects.” Phytotherapy Research: PTR 27 (11): 1723–28. https://doi.org/10.1002/ptr.4916.

Sarris, Jerome. 2018. “Herbal Medicines in the Treatment of Psychiatric Disorders: 10-Year Updated Review.” Phytotherapy Research: PTR 32 (7): 1147–62. https://doi.org/10.1002/ptr.6055.

Sarris, Jerome, Gerard J. Byrne, Chad A. Bousman, Lachlan Cribb, Karen M. Savage, Oliver Holmes, Jenifer Murphy, et al. 2020. “Kava for Generalised Anxiety Disorder: A 16-Week Double-Blind, Randomised, Placebo-Controlled Study.” The Australian and New Zealand Journal of Psychiatry 54 (3): 288–97. https://doi.org/10.1177/0004867419891246.

Sarris, Jerome, Emma LaPorte, and Isaac Schweitzer. 2011. “Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology.” The Australian and New Zealand Journal of Psychiatry 45 (1): 27–35. https://doi.org/10.3109/00048674.2010.522554.

Sarris, Jerome, Erica McIntyre, and David A. Camfield. 2013. “Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence.” CNS Drugs 27 (4): 301–19. https://doi.org/10.1007/s40263-013-0059-9.

Sarris, Jerome, A. Scholey, Isaac Schweitzer, Chad Bousman, Emma LaPorte, Chee Ng, Greg Murray, and C. Stough. 2012. “The Acute Effects of Kava and Oxazepam on Anxiety, Mood, Neurocognition; and Genetic Correlates: A Randomized, Placebo-Controlled, Double-Blind Study.” Human Psychopharmacology: Clinical and Experimental 27 (3): 262–69. https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.2216.

Sarris, Jerome, Con Stough, Chad A. Bousman, Zahra T. Wahid, Greg Murray, Rolf Teschke, Karen M. Savage, Ashley Dowell, Chee Ng, and Isaac Schweitzer. 2013. “Kava in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.” Journal of Clinical Psychopharmacology 33 (5): 643. https://doi.org/10.1097/JCP.0b013e318291be67.

Sarris, Jerome, Rolf Teschke, Con Stough, Andrew Scholey, and Isaac Schweitzer. 2011. “Re-Introduction of Kava (Piper Methysticum) to the EU: Is There a Way Forward?” Planta Medica 77 (2): 107–10. https://doi.org/10.1055/s-0030-1250290.

Savage, Karen M., Con K. Stough, Gerard J. Byrne, Andrew Scholey, Chad Bousman, Jenifer Murphy, Patricia Macdonald, et al. 2015. “Kava for the Treatment of Generalised Anxiety Disorder (K-GAD): Study Protocol for a Randomised Controlled Trial.” Trials 16 (November): 493. https://doi.org/10.1186/s13063-015-0986-5.

Schelosky, L., C. Raffauf, K. Jendroska, and W. Poewe. 1995. “Kava and Dopamine Antagonism.” Journal of Neurology, Neurosurgery, and Psychiatry 58 (5): 639–40. https://doi.org/10.1136/jnnp.58.5.639.

Scherer, J. 1998. “Kava-Kava Extract in Anxiety Disorders: An Outpatient Observational Study.” Advances in Therapy 15 (4): 261–69. http://dx.doi.org/.

Schmidt, M. 2016. “Clinical Summary Kava Extract.”

Schmidt, N., and B. Ferger. 2001. “Neuroprotective Effects of (+/-)-Kavain in the MPTP Mouse Model of Parkinson’s Disease.” Synapse 40 (1): 47–54. https://doi.org/10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S.

Segone, Ramoagi T., Sidonie Y. Tankeu, Weiyang Chen, Sandra Combrinck, Mathias Schmidt, and Alvaro Viljoen. 2020. “Rapid Differentiation of Piper Methysticum (kava) Plant Parts Using Single Point and Imaging Vibrational Spectroscopy.” Journal of Applied Research on Medicinal and Aromatic Plants 16 (100235): 100235. https://doi.org/10.1016/j.jarmap.2019.100235.

Shaik, Ahmad Ali, David Lee Hermanson, and Chengguo Xing. 2009. “Identification of Methysticin as a Potent and Non-Toxic NF-kappaB Inhibitor from Kava, Potentially Responsible for Kava’s Chemopreventive Activity.” Bioorganic & Medicinal Chemistry Letters 19 (19): 5732–36. https://doi.org/10.1016/j.bmcl.2009.08.003.

Sharma, Ankit, Rahul Anchariya, and Chetan Dubey. 2020. “A Review on Anti-Stress Activity of Piper Methysticum.” Asian Journal of Pharmaceutical Research and Development 8 (4): 130–36. https://doi.org/10.22270/ajprd.v8i4.688.

Sharma, Ankit, Mohammad Mukim, Rahul Ancheria, and Hrishab Jangid. 2021. “A Research Article on Antistress Activity of Herbal Extract Oil of Piper Methysticum on Wistar Albino.” Asian Journal of Pharmaceutical Research and Development 9 (1): 117–29. https://doi.org/10.22270/ajprd.v9i1.892.

Shimoda, L. M. N., A. Showman, J. D. Baker, I. Lange, D. L. Koomoa, A. J. Stokes, R. P. Borris, and H. Turner. 2015. “Differential Regulation of Calcium Signalling Pathways by Components of Piper Methysticum (’Awa).” Phytotherapy Research: PTR 29 (4): 582–90. https://doi.org/10.1002/ptr.5291.

Shimoda, Lori M. N., Christy Park, Alexander J. Stokes, Henry Halenani Gomes, and Helen Turner. 2012. “Pacific Island ’Awa (Kava) Extracts, but Not Isolated Kavalactones, Promote Proinflammatory Responses in Model Mast Cells.” Phytotherapy Research: PTR 26 (12): 1934–41. https://doi.org/10.1002/ptr.4652.

Shinomiya, Kazuaki, Toshio Inoue, Yoshiaki Utsu, Shin Tokunaga, Takayoshi Masuoka, Asae Ohmori, and Chiaki Kamei. 2005. “Effects of Kava-Kava Extract on the Sleep-Wake Cycle in Sleep-Disturbed Rats.” Psychopharmacology 180 (3): 564–69. https://doi.org/10.1007/s00213-005-2196-4.

Showman, A. 2017. “CHEMICAL AND MICROBIAL ECOLOGY OF ’AWA, PIPER METHYSTICUM (G. FORST).” Molecular Biosciences and Bioengineering.

Showman, Angelique F., Jonathan D. Baker, Christina Linares, Chrystie K. Naeole, Robert Borris, Edward Johnston, Jerry Konanui, and Helen Turner. 2015. “Contemporary Pacific and Western Perspectives on `awa (Piper Methysticum) Toxicology.” Fitoterapia 100 (January): 56–67. https://doi.org/10.1016/j.fitote.2014.11.012.

Siméoni, Patricia, and Vincent Lebot. 2002. “Identification of Factors Determining Kavalactone Content and Chemotype in Kava (Piper Methysticum Forst. F.).” Biochemical Systematics and Ecology 30 (5): 413–24. https://doi.org/10.1016/S0305-1978(01)00093-X.

Singh, Y. N. 1983. “Effects of Kava on Neuromuscular Transmission and Muscle Contractility.” Journal of Ethnopharmacology 7 (3): 267–76. https://doi.org/10.1016/0378-8741(83)90002-8.

———. 1992. “Kava: An Overview.” Journal of Ethnopharmacology 37 (1): 13–45. https://doi.org/10.1016/0378-8741(92)90003-a.

Singh, Yadhu N. 2005. “Potential for Interaction of Kava and St. John’s Wort with Drugs.” Journal of Ethnopharmacology 100 (1-2): 108–13. https://doi.org/10.1016/j.jep.2005.05.014.

———. 2009. “Kava: An Old Drug in a New World.” Cultural Critique 71 (1): 107–28. https://doi.org/10.1353/cul.0.0029.

Singh, Yadhu N., and Ashwini K. Devkota. 2003. “Aqueous Kava Extracts Do Not Affect Liver Function Tests in Rats.” Planta Medica 69 (6): 496–99. https://doi.org/10.1055/s-2003-40658.

Singh, Yadhu N., and Nirbhay N. Singh. 2002. “Therapeutic Potential of Kava in the Treatment of Anxiety Disorders.” CNS Drugs 16 (11): 731–43. https://doi.org/10.2165/00023210-200216110-00002.

Skov, Steven J., Tanya N. Chikritzhs, Shu Q. Li, Sabine Pircher, and Steven Whetton. 2010. “How Much Is Too Much? Alcohol Consumption and Related Harm in the Northern Territory.” The Medical Journal of Australia 193 (5): 269–72. https://doi.org/10.5694/j.1326-5377.2010.tb03905.x.

Smith, Katelyn, and Claudia Leiras. 2018. “The Effectiveness and Safety of Kava Kava for Treating Anxiety Symptoms: A Systematic Review and Analysis of Randomized Clinical Trials.” Complementary Therapies in Clinical Practice 33 (November): 107–17. https://doi.org/10.1016/j.ctcp.2018.09.003.

Smith, Thomas E., Mabel Djang, Alan J. Velander, C. Wade Downey, Kathleen A. Carroll, and Sophie Van Alphen. 2004. “Versatile Asymmetric Synthesis of the Kavalactones: First Synthesis of (+)-Kavain.” Organic Letters 6 (14): 2317–20. https://doi.org/10.1021/ol0493960.

Sofer, Michael. 2007. “Yaqona and the Fijian Periphery Revisited.” Asia Pacific Viewpoint 48 (2): 234–49. https://doi.org/10.1111/j.1467-8373.2007.00342.x.

Song, Jia-Ling, Bai-Lin Li, Yao Yuan, Ling-Hui Nie, Jia Niu, David Chiu, Zhi-Fang Xu, Jie-Wei Wu, and Sheng-Xiang Qiu. 2017. “Yangonindimers A-C, Three New Kavalactone Dimers from Piper Methysticum (kava).” Natural Product Research 31 (21): 2459–66. https://doi.org/10.1080/14786419.2017.1312395.

Sorrentino, L., A. Capasso, and M. Schmidt. 2006. “Safety of Ethanolic Kava Extract: Results of a Study of Chronic Toxicity in Rats.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 13 (8): 542–49. https://doi.org/10.1016/j.phymed.2006.01.006.

SStofer, William D. 2002. “Kavain Attenuates Vascular Contractility Through.” Planta Medica 68: 784–89.

Stefan, U. 2009. “Toxic Hepatitis After Consumption of Traditional Kava Preparation.” Journal of Travel Medicine 16 (1). https://doi.org/10.1111/j.1708-8305.2008.00259.x.

Steiner, G. G. 2000. “The Correlation between Cancer Incidence and Kava Consumption.” Hawaii Medical Journal 59 (11): 420–22. https://pubmed.ncbi.nlm.nih.gov/11149250.

Stickel, Felix, Hans-Martin Baumüller, Karlheinz Seitz, Dimitrios Vasilakis, Gerhard Seitz, Helmut K. Seitz, and Detlef Schuppan. 2003. “Hepatitis Induced by Kava (Piper Methysticum Rhizoma).” Journal of Hepatology 39 (1): 62–67. https://doi.org/10.1016/s0168-8278(03)00175-2.

Tabudravu, J. N., and M. Jaspars. 2005. “Anticancer Activities of Constituents of Kava (Piper Methysticum).” The South Pacific Journal of Natural and Applied Sciences 23 (1): 26. https://doi.org/10.1071/sp05005.

Tanaka, Arisa, Nanako Hamada, Yasunori Fujita, Tomohiro Itoh, Yoshinori Nozawa, Munekazu Iinuma, and Masafumi Ito. 2010. “A Novel Kavalactone Derivative Protects against H2O2-Induced PC12 Cell Death via Nrf2/ARE Activation.” Bioorganic & Medicinal Chemistry 18 (9): 3133–39. https://doi.org/10.1016/j.bmc.2010.03.034.

Tang, Su-Ni, Jinhui Zhang, Peixin Jiang, Palika Datta, Pablo Leitzman, M. Gerard O’Sullivan, Cheng Jiang, Chengguo Xing, and Junxuan Lü. 2016. “Gene Expression Signatures Associated with Suppression of TRAMP Prostate Carcinogenesis by a Kavalactone-Rich Kava Fraction.” Molecular Carcinogenesis 55 (12): 2291–2303. https://doi.org/10.1002/mc.22469.

Tang, Xiaoren, and Salomon Amar. 2016. “Kavain Involvement in LPS-Induced Signaling Pathways.” Journal of Cellular Biochemistry 117 (10): 2272–80. https://doi.org/10.1002/jcb.25525.

Tang, Yaxiong, Xuesen Li, Zhongbo Liu, Anne R. Simoneau, Jun Xie, and Xiaolin Zi. 2010. “Flavokawain B, a Kava Chalcone, Induces Apoptosis via up-Regulation of Death-Receptor 5 and Bim Expression in Androgen Receptor Negative, Hormonal Refractory Prostate Cancer Cell Lines and Reduces Tumor Growth.” International Journal of Cancer. Journal International Du Cancer 127 (8): 1758–68. https://doi.org/10.1002/ijc.25210.

Tang, Yaxiong, Anne R. Simoneau, Jun Xie, Babbak Shahandeh, and Xiaolin Zi. 2008. “Effects of the Kava Chalcone Flavokawain A Differ in Bladder Cancer Cells with Wild-Type versus Mutant p53.” Cancer Prevention Research 1 (6): 439–51. https://doi.org/10.1158/1940-6207.CAPR-08-0165.

Tang, Yijin, and Christine Fields. 2019. “A UHPLC-UV Method Development and Validation for Determining Kavalactones and Flavokavains in Piper Methysticum (Kava).” Molecules (Basel, Switzerland) 24 (7): 1245. https://doi.org/10.3390/molecules24071245.

Tarbah, F., H. Mahler, B. Kardel, W. Weinmann, D. Hafner, and Th Daldrup. 2003. “Kinetics of Kavain and Its Metabolites after Oral Application.” Journal of Chromatography B 789 (1): 115–30. https://doi.org/10.1016/S1570-0232(03)00046-1.

Tawfiq, Rasha A., Noha N. Nassar, Wafaa I. El-Eraky, and Ezzeldein S. El-Denshary. 2014. “Enhanced Efficacy and Reduced Side Effects of Diazepam by Kava Combination.” Journal of Advertising Research 5 (5): 587–94. https://doi.org/10.1016/j.jare.2013.08.002.

Taylor, Dr M., and Luseane Taufa. 1997. “Decontamination of Kava (Piper Methysticum) for in Vitro Propagation.” In International Symposium on Biotechnology of Tropical and Subtropical Species Part 2 461, 267–74. actahort.org. https://www.actahort.org/books/461/461_29.htm.

Taylor, John P. 2010. “Janus and the Siren’s Call: Kava and the Articulation of Gender and Modernity in Vanuatu.” The Journal of the Royal Anthropological Institute 16 (2): 279–96. https://doi.org/10.1111/j.1467-9655.2010.01625.x.

Tecun, Arcia. 2017. “TONGAN KAVA: PERFORMANCE, ADAPTATION, AND IDENTITY IN DIASPORA.” None.

Tecun, Arcia, Robert Reeves, and Marlena Wolfgramm. 2020. “The Past Before Us: A Brief History of Tongan Kava.” The Journal of the Polynesian Society. Polynesian Society 129 (2): 171–92. https://doi.org/10.15286/jps.129.2.171-192.

Teschke, R., J. Fuchs, R. Bahre, A. Genthner, and A. Wolff. 2010. “Kava Hepatotoxicity: Comparative Study of Two Structured Quantitative Methods for Causality Assessment.” Journal of Clinical Pharmacy and Therapeutics 35 (5): 545–63. https://doi.org/10.1111/j.1365-2710.2009.01131.x.

Teschke, R., W. Gaus, and D. Loew. 2003. “Kava Extracts: Safety and Risks Including Rare Hepatotoxicity.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 10 (5): 440–46. https://doi.org/10.1078/0944-7113-00314.

Teschke, Rolf. 2010a. “Kava Hepatotoxicity--a Clinical Review.” Annals of Hepatology 9 (3): 251–65. https://doi.org/10.1016/S1665-2681(19)31634-5.

———. 2010b. “Kava Hepatotoxicity: Pathogenetic Aspects and Prospective Considerations.” Liver International: Official Journal of the International Association for the Study of the Liver 30 (9): 1270–79. https://doi.org/10.1111/j.1478-3231.2010.02308.x.

Teschke, Rolf, Alexander Genthner, and Albrecht Wolff. 2009. “Kava Hepatotoxicity: Comparison of Aqueous, Ethanolic, Acetonic Kava Extracts and Kava-Herbs Mixtures.” Journal of Ethnopharmacology 123 (3): 378–84. https://doi.org/10.1016/j.jep.2009.03.038.

Teschke, Rolf, and Vincent Lebot. 2011. “Proposal for a Kava Quality Standardization Code.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 49 (10): 2503–16. https://doi.org/10.1016/j.fct.2011.06.075.

Teschke, Rolf, Samuel X. Qiu, and Vincent Lebot. 2011. “Herbal Hepatotoxicity by Kava: Update on Pipermethystine, Flavokavain B, and Mould Hepatotoxins as Primarily Assumed Culprits.” Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 43 (9): 676–81. https://doi.org/10.1016/j.dld.2011.01.018.

Teschke, Rolf, Samuel X. Qiu, Tran Dang Xuan, and Vincent Lebot. 2011. “Kava and Kava Hepatotoxicity: Requirements for Novel Experimental, Ethnobotanical and Clinical Studies Based on a Review of the Evidence.” Phytotherapy Research: PTR 25 (9): 1263–74. https://doi.org/10.1002/ptr.3464.

Teschke, Rolf, Jerome Sarris, Xaver Glass, and Johannes Schulze. 2011. “Kava, the Anxiolytic Herb: Back to Basics to Prevent Liver Injury?: Kava, back to Basics?” British Journal of Clinical Pharmacology 71 (3): 445–48. https://doi.org/10.1111/j.1365-2125.2010.03775.x.

Teschke, Rolf, Jerome Sarris, and Vincent Lebot. 2011. “Kava Hepatotoxicity Solution: A Six-Point Plan for New Kava Standardization.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 18 (2-3): 96–103. https://doi.org/10.1016/j.phymed.2010.10.002.

———. 2013. “Contaminant Hepatotoxins as Culprits for Kava Hepatotoxicity--Fact or Fiction?” Phytotherapy Research: PTR 27 (3): 472–74. https://doi.org/10.1002/ptr.4729.

Teschke, Rolf, Alexander Schwarzenboeck, and Karl-Heinz Hennermann. 2008. “Kava Hepatotoxicity: A Clinical Survey and Critical Analysis of 26 Suspected Cases.” European Journal of Gastroenterology & Hepatology 20 (12): 1182–93. https://doi.org/10.1097/MEG.0b013e3283036768.

Thompson, Richard, Willibald Ruch, and Rüdiger U. Hasenöhrl. 2004. “Enhanced Cognitive Performance and Cheerful Mood by Standardized Extracts of Piper Methysticum (Kava-Kava).” Human Psychopharmacology: Clinical and Experimental 19 (4): 243–50. https://onlinelibrary.wiley.com/doi/abs/10.1002/hup.581.

Thomsen, Michael, and Mathias Schmidt. 2021. “Health Policy versus Kava (Piper Methysticum): Anxiolytic Efficacy May Be Instrumental in Restoring the Reputation of a Major South Pacific Crop.” Journal of Ethnopharmacology 268 (March): 113582. https://doi.org/10.1016/j.jep.2020.113582.

Titcomb, Margaret. 1948. “Kava in Hawaii.” The Journal of the Polynesian Society. Polynesian Society 57 (2): 105–71. https://doi.org/10.2307/20703155.

Tomlinson, Matt. 2004. “Perpetual Lament: Kava-Drinking, Christianity and Sensations of Historical Decline in Fiji.” The Journal of the Royal Anthropological Institute 10 (3): 653–73. http://www.jstor.org/stable/3803799.

———. 2006. “A CONSUMING TRADITION Kava Drinking in Fiji.” In Consuming Tradition, Manufacturing Heritage - Global Norms and Urban Forms in the Age of Tourism, edited by Nezar Alsayyad, 48:8–17. Routledge. https://doi.org/10.4324/9781315011486.

———. 2007. “Everything and Its Opposite: Kava Drinking in Fiji.” Anthropological Quarterly 80 (4): 1065–81. http://www.jstor.org/stable/30052773.

Triolet, Julie, Ahmad Ali Shaik, Daniel D. Gallaher, Michael G. O’Sullivan, and Chengguo Xing. 2012. “Reduction in Colon Cancer Risk by Consumption of Kava or Kava Fractions in Carcinogen-Treated Rats.” Nutrition and Cancer 64 (6): 838–46. https://doi.org/10.1080/01635581.2012.689917.

Tugcu, Gulcin, Hasan Kırmızıbekmez, and Ahmet Aydın. 2020. “The Integrated Use of in Silico Methods for the Hepatotoxicity Potential of Piper Methysticum.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 145 (November): 111663. https://doi.org/10.1016/j.fct.2020.111663.

“TURMOIL AT VANUATU COMMODITIES BOARD.” n.d. Accessed May 3, 2021. http://www.pireport.org/articles/2009/04/22/turmoil-vanuatu-commodities-board.

Turner, James W. 1986. “‘The Water of Life’: Kava Ritual and the Logic of Sacrifice.” Ethnology 25 (3): 203–14. https://doi.org/10.2307/3773584.

Turner, James West. 2012. “LISTENING TO THE ANCESTORS: KAVA AND THE LAPITA PEOPLES.” Ethnology 51 (1).

Uebelhock, R., L. Fronke, and H-1 Schewe. 1998. “Inhibition of Platelet MAO-6 by Kava Pyrone-Enriched Extract from Piper Methysticum Forster (Kava-Kava).” Pharmacopsychiatry 31 (5): 187–92. https://doi.org/10.1055/s-2007-979325.

Ulbricht, Catherine, Ethan Basch, Heather Boon, Edzard Ernst, Paul Hammerness, David Sollars, Candy Tsourounis, Jen Woods, and Stephen Bent. 2005. “Safety Review of Kava (Piper Methysticum) by the Natural Standard Research Collaboration.” Expert Opinion on Drug Safety 4 (4): 779–94. https://doi.org/10.1517/14740338.4.4.779.

Upadhyay, Atul, Emmy Tuenter, Rizwan Ahmad, Adnan Amin, Vasiliki Exarchou, Sandra Apers, Nina Hermans, and Luc Pieters. 2014. “Kavalactones, a Novel Class of Protein Glycation and Lipid Peroxidation Inhibitors.” Planta Medica 80 (12): 1001–8. https://doi.org/10.1055/s-0034-1382949.

Uzomba, N. I., Ajah Obinna, and E. C. Amaralam. 2020. “PHYTOCHEMICAL AND NUTRITIONAL COMPOSITION OF PIPER METHYSTICUM LEAEVES.” World Journal of Pharmaceutical Research 9 (3): 220–26. https://doi.org/10.20959/wjpr20203-16848.

Va’a, Unasa Leulu Fplise. 2010. “Indigenous Anthropology and the Kava Myth in Manu’a.” Pacific Studies 33: 19–19. http://ojs-dev.byuh.edu/index.php/pacific/article/download/1165/1116.

Van, Truong Mai, Tran Dang Xuan, Truong Ngoc Minh, and Nguyen Van Quan. 2018. “Isolation and Purification of Potent Growth Inhibitors from Piper Methysticum Root.” Molecules 23 (8). https://doi.org/10.3390/molecules23081907.

Vandenbroucke, Henri, Pierre Mournet, Roger Malapa, Jean-Christophe Glaszmann, Hana Chaïr, and Vincent Lebot. 2015. “Comparative Analysis of Genetic Variation in Kava (Piper Methysticum) Assessed by SSR and DArT Reveals Zygotic Foundation and Clonal Diversification.” Genome / National Research Council Canada = Genome / Conseil National de Recherches Canada 58 (1): 1–11. https://doi.org/10.1139/gen-2014-0166.

Vanuatu. 2002. “Kava Act 2002.” 7. Republic Of Vanuatu. https://biosecurity.gov.vu/images/Export/kava-act-2002.pdf.

Visser, Edward P. 1994. “SKELETAL EVIDENCE OF KAVA USE IN PREHISTORIC FIJI.” The Journal of the Polynesian Society. Polynesian Society 103 (3): 299–317. http://www.jstor.org/stable/20706579.

Volgin, Andrey, Longen Yang, Tamara Amstislavskaya, Konstantin Demin, Dongmei Wang, Dongni Yan, Jingtao Wang, et al. 2020. “DARK Classics in Chemical Neuroscience: Kava.” ACS Chemical Neuroscience, January. https://doi.org/10.1021/acschemneuro.9b00587.

Volz HP, Kieser M. 1997. “Kava-Kava Extract WS 1490 versus Placebo in Anxiety Disorders--a Randomized Placebo-Controlled 25-Week Outpatient Trial.” Pharmacopsychiatry 30 (1): 1–5. https://doi.org/10.1055/s-2007-979474.

Wainiqolo, Iris, Bridget Kool, Vili Nosa, and Shanthi Ameratunga. 2015. “Is Driving under the Influence of Kava Associated with Motor Vehicle Crashes? A Systematic Review of the Epidemiological Literature.” Australian and New Zealand Journal of Public Health 39 (5): 495–99. https://doi.org/10.1111/1753-6405.12435.

Walden, J., J. von Wegerer, U. Winter, M. Berger, and H. Grunze. 1997. “Effects of Kawain and Dihydromethysticin on Field Potential Changes in the Hippocampus.” Progress in Neuro-Psychopharmacology & Biological Psychiatry 21 (4): 697–706. https://doi.org/10.1016/s0278-5846(97)00042-0.

Wang, Dongmei, Longen Yang, Jingtao Wang, Guojun Hu, Ziyuan Liu, Dongni Yan, Nazar Serikuly, et al. 2020. “Behavioral and Physiological Effects of Acute and Chronic Kava Exposure in Adult Zebrafish.” Neurotoxicology and Teratology 79 (May): 106881. https://doi.org/10.1016/j.ntt.2020.106881.

Wang, Jun, Weiyue Qu, Harry C. Bittenbender, and Qing X. Li. 2015. “Kavalactone Content and Chemotype of Kava Beverages Prepared from Roots and Rhizomes of Isa and Mahakea Varieties and Extraction Efficiency of Kavalactones Using Different Solvents.” Journal of Food Science and Technology 52 (2): 1164–69. https://doi.org/10.1007/s13197-013-1047-2.

Wang, Yi, Shainnel O. Eans, Heather M. Stacy, Sreekanth C. Narayanapillai, Abhisheak Sharma, Naomi Fujioka, Linda Haddad, Jay McLaughlin, Bonnie A. Avery, and Chengguo Xing. 2018. “A Stable Isotope Dilution Tandem Mass Spectrometry Method of Major Kavalactones and Its Applications.” PloS One 13 (5): e0197940. https://doi.org/10.1371/journal.pone.0197940.

Wang, Yi, Sreekanth C. Narayanapillai, Katelyn M. Tessier, Lori G. Strayer, Pramod Upadhyaya, Qi Hu, Rick Kingston, et al. 2020. “The Impact of One-Week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-Based Carcinogenesis Risk among Active Smokers.” Cancer Prevention Research 13 (5): 483–92. https://doi.org/10.1158/1940-6207.CAPR-19-0501.

Warburton, Emma, Paul L. Norris, and Heidi Goenaga-Infante. 2007. “Comparison of the Capabilities of Accelerated Solvent Extraction and Sonication as Extraction Techniques for the Quantification of Kavalactones in Piper Methysticum (Kava) Roots by High Performance Liquid Chromatography with Ultra Violet Detection.” Phytochemical Analysis: PCA 18 (2): 98–102. https://doi.org/10.1002/pca.955.

Watkins, L. L., K. M. Connor, and J. R. Davidson. 2001. “Effect of Kava Extract on Vagal Cardiac Control in Generalized Anxiety Disorder: Preliminary Findings.” Journal of Psychopharmacology 15 (4): 283–86. https://doi.org/10.1177/026988110101500407.

Weiss, Johanna, Alexandra Sauer, Andreas Frank, and Matthias Unger. 2005. “Extracts and Kavalactones of Piper Methysticum G. Forst (kava-Kava) Inhibit P-Glycoprotein in Vitro.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 33 (11): 1580–83. https://doi.org/10.1124/dmd.105.005892.

White, C. Michael. 2018. “The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With Kava.” Journal of Clinical Pharmacology 58 (11): 1396–1405. https://doi.org/10.1002/jcph.1263.

Whitton, Peter A. 2004. “Response to Schmidt ‘Are Kavalactones the Hepatotoxic Principle of Kava Extracts? The Pitfalls of the Glutathione Theory.’” The Journal of Alternative and Complementary Medicine 9 (2): 187–88. https://doi.org/10.1089/10755530360623293.

Whitton, Peter A., Andrew Lau, Alicia Salisbury, Julie Whitehouse, and Christine S. Evans. 2003. “Kava Lactones and the Kava-Kava Controversy.” Phytochemistry 64 (3): 673–79. https://doi.org/10.1016/s0031-9422(03)00381-9.

Winter, Kawika, and Will McClatchey. 2009. “The Quantum Co-Evolution Unit: An Example of ‘Awa (Kava—Piper Methysticum G. Foster) in Hawaiian Culture.” Economic Botany 63 (4): 353–62. https://doi.org/10.1007/s12231-009-9089-0.

Witte, Steffen, Dieter Loew, and Wilhelm Gaus. 2005. “Meta-Analysis of the Efficacy of the Acetonic Kava-Kava Extract WS1490 in Patients with Non-Psychotic Anxiety Disorders.” Phytotherapy Research: PTR 19 (3): 183–88. https://doi.org/10.1002/ptr.1609.

Wruck, Christoph J., Mario E. Götz, Thomas Herdegen, Deike Varoga, Lars-Ove Brandenburg, and Thomas Pufe. 2008. “Kavalactones Protect Neural Cells against Amyloid Beta Peptide-Induced Neurotoxicity via Extracellular Signal-Regulated Kinase 1/2-Dependent Nuclear Factor Erythroid 2-Related Factor 2 Activation.” Molecular Pharmacology 73 (6): 1785–95. https://doi.org/10.1124/mol.107.042499.

Wu, D., L. Yu, M. G. Nair, D. L. DeWitt, and R. S. Ramsewak. 2002. “Cyclooxygenase Enzyme Inhibitory Compounds with Antioxidant Activities from Piper Methysticum (kava Kava) Roots.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 9 (1): 41–47. https://doi.org/10.1078/0944-7113-00068.

Xuan, T. D., A. A. Elzaawely, M. Fukuta, and S. Tawata. 2006. “Herbicidal and Fungicidal Activities of Lactones in Kava (Piper Methysticum).” Journal of Agricultural and Food Chemistry 54 (3): 720–25. https://doi.org/10.1021/jf0519461.

Xuan, Tran Dang, Masakazu Fukuta, Ao Chang Wei, Abdelnaser Abdelghany Elzaawely, Tran Dang Khanh, and Shinkichi Tawata. 2008. “Efficacy of Extracting Solvents to Chemical Components of Kava (Piper Methysticum) Roots.” Journal of Natural Medicines 62 (2): 188–94. https://doi.org/10.1007/s11418-007-0203-2.

Yang, Jian Xiang. 2019. “A New Kavalactone Dimer from Piper Methysticum.” Chemistry of Natural Compounds 55 (4): 606–9. https://doi.org/10.1007/s10600-019-02759-8.

Yang, Xi, and William F. Salminen. 2011. “Kava Extract, an Herbal Alternative for Anxiety Relief, Potentiates Acetaminophen-Induced Cytotoxicity in Rat Hepatic Cells.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 18 (7): 592–600. https://doi.org/10.1016/j.phymed.2011.02.006.

Yiannis, Callisthenis, Kevin Huang, An Nhien Tran, Cathy Zeng, Emily Dao, Oliver Baselyous, Muaaz Adil Mithwani, et al. 2020. “Protective Effect of Kava Constituents in an in Vitro Model of Oral Mucositis.” Journal of Cancer Research and Clinical Oncology 146 (7): 1801–11. https://doi.org/10.1007/s00432-020-03253-3.

Young, Michael W. 1995. “Kava and Christianity in Central Vanuatu: With an Appendix on the Ethnography of Kava Drinking in Nikaura, Epi.” Canberra Anthropology 18 (1-2): 61–96. https://www.tandfonline.com/doi/pdf/10.1080/03149099509508409.

Yuan, Chun-Su, Lucy Dey, Anbao Wang, Sangeeta Mehendale, Jing-Tian Xie, Han H. Aung, and Michael K. Ang-Lee. 2002. “Kavalactones and Dihydrokavain Modulate GABAergic Activity in a Rat Gastric-Brainstem Preparation.” Planta Medica 68 (12): 1092–96. https://doi.org/10.1055/s-2002-36338.

Zhang, Nenling, Linjing Wu, Xiang Liu, and Xiangchun Shen. 2018. “Plant-Derived Kavalactones and Their Bioactivities.” Le Medecin de Reserve 2 (1): 20170019–20170013. https://doi.org/10.21127/yaoyimr20170019.

Zhang, Yidan, Yoav S. Zvi, Brian Batko, Nikolas Zaphiros, Edmond F. O’Donnell, Jichuan Wang, Kenji Sato, et al. 2018. “Down-Regulation of Skp2 Expression Inhibits Invasion and Lung Metastasis in Osteosarcoma.” Scientific Reports 8 (1): 14294. https://doi.org/10.1038/s41598-018-32428-9.

Zhao, Xiaojun, Chao Su, Ruru Ren, Bo Zhang, Yingli Wang, Xiaojuan Su, Fangfang Lu, et al. 2021. “Simultaneous Determination of Both Kavalactones and Flavokawains Constituents by Different Single Marker in Kava.” Journal of Separation Science, May. https://doi.org/10.1002/jssc.202100198.

Zhou, Ping, Shimon Gross, Ji-Hua Liu, Bo-Yang Yu, Ling-Ling Feng, Jan Nolta, Vijay Sharma, David Piwnica-Worms, and Samuel X. Qiu. 2010. “Flavokawain B, the Hepatotoxic Constituent from Kava Root, Induces GSH-Sensitive Oxidative Stress through Modulation of IKK/NF-kappaB and MAPK Signaling Pathways.” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 24 (12): 4722–32. https://doi.org/10.1096/fj.10-163311.

Zi, Xiaolin, and Anne R. Simoneau. 2005. “Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice.” Cancer Research 65 (8): 3479–86. https://doi.org/10.1158/0008-5472.CAN-04-3803.

Zou, L., G. L. Henderson, M. R. Harkey, Y. Sakai, and A. Li. 2004. “Effects of Kava (Kava-Kava, ’Awa, Yaqona, Piper Methysticum) on c-DNA-Expressed Cytochrome P450 Enzymes and Human Cryopreserved Hepatocytes.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 11 (4): 285–94. https://doi.org/10.1078/0944711041495263.

Zou, Lihong, Martha R. Harkey, Gary L. Henderson, and Laura E. Dike. 2004. “Kava Does Not Display Metabolic Toxicity in a Homogeneous Cellular Assay.” Planta Medica 70 (4): 289–92. https://doi.org/10.1055/s-2004-818937.
 
Last edited:

Kapmcrunk

The Kaptain (40g)
KavaForums Founder
more, lol

Anke, Jennifer, and Iqqbal Ramzan. 2004. “Kava Hepatotoxicity: Are We Any Closer to the Truth?” Planta Medica 70: 193–96. https://doi.org/10.1055/s-2004-815533.

Baker, Jonathan D. 2011. “Tradition and Toxicity: Evidential Cultures in the Kava Safety Debate.” Social Studies of Science 41 (3): 361–84. https://doi.org/10.1177/0306312710395341.

Bauer, Rudolf, Brigitte & Kopp, and A. Nahrstedt. 2003. “Relevant Hepatotoxic Effects of Kava Still Need to Be Proven: A Statement of the Society for Medicinal Plant Research.” Planta Medica 69 (11): 971–72. https://doi.org/10.1055/s-2003-45140.

Becker, Matheus William, Emerson Matheus Silva Lourençone, Alexandre Formighieri De Mello, Aline Branco, Edison Moraes Rodrigues Filho, Celso Ronaldo Blatt, Carlos Augusto Mallmann, Maurício Schneider, Rita Catalina Aquino Caregnato, and Carine Raquel Blatt. 2019. “Liver Transplantation and the Use of KAVA: Case Report.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 56 (March): 21–26. https://doi.org/10.1016/j.phymed.2018.08.011.

Behl, Mamta, Abraham Nyska, Rajendra S. Chhabra, Gregory S. Travlos, Laurene M. Fomby, Barney R. Sparrow, Milton R. Hejtmancik, and Po C. Chan. 2011. “Liver Toxicity and Carcinogenicity in F344/N Rats and B6C3F1 Mice Exposed to Kava Kava.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 49 (11): 2820–29. https://doi.org/10.1016/j.fct.2011.07.067.

Brown, Amy C., Janet Onopa, Peter Holck, Pakieli Kaufusi, Derek Kabasawa, Winston J. Craig, Klaus Dragull, Arieh M. Levine, and Jonathan D. Baker. 2007. “Traditional Kava Beverage Consumption and Liver Function Tests in a Predominantly Tongan Population in Hawaii.” Clinical Toxicology 45 (5): 549–56. https://doi.org/10.1080/15563650701365875.

Chou, Tsui-Wei, Jia-Hua Feng, Chi-Chang Huang, Ya-Wen Cheng, Shih-Chang Chien, Sheng-Yang Wang, and Lie-Fen Shyur. 2013. “A Plant Kavalactone Desmethoxyyangonin Prevents Inflammation and Fulminant Hepatitis in Mice.” PloS One 8 (10): e77626. https://doi.org/10.1371/journal.pone.0077626.

Clouatre, Dallas L. 2004. “Kava Kava: Examining New Reports of Toxicity.” Toxicology Letters 150: 85–96. https://doi.org/10.1016/j.toxlet.2003.07.005.

Clough, Alan R., Ross S. Bailie, and Bart Currie. 2003. “Liver Function Test Abnormalities in Users of Aqueous Kava Extracts.” Journal of Toxicology. Clinical Toxicology 41 (6): 821–29. https://doi.org/10.1081/clt-120025347.

Coulter, David, Tamayo Carmen Sotheeswaran Subramaniam, Catherine Ulbricht, and World Health Organization. 2007. “Assessment of the Risk of Hepatotoxicity with Kava Products.pdf.” World Health Organization.

Currie, Bart J., and Alan R. Clough. 2003. “Kava Hepatotoxicity with Western Herbal Products: Does It Occur with Traditional Kava Use?” The Medical Journal of Australia. mja.com.au. https://doi.org/10.5694/j.1326-5377.2003.tb05279.x.

Danan, Gaby, and Rolf Teschke. 2015. “RUCAM in Drug and Herb Induced Liver Injury: The Update.” International Journal of Molecular Sciences 17 (1). https://doi.org/10.3390/ijms17010014.

DiSilvestro, Robert A., Wenyi Zhang, and David J. DiSilvestro. 2007. “Kava Feeding in Rats Does Not Cause Liver Injury nor Enhance Galactosamine-Induced Hepatitis.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 45 (7): 1293–1300. https://doi.org/10.1016/j.fct.2007.01.015.

Escher, M., J. Desmeules, E. Giostra, and G. Mentha. 2001. “Hepatitis Associated with Kava, a Herbal Remedy for Anxiety.” BMJ 322 (7279): 139. https://doi.org/10.1136/bmj.322.7279.139.

Food and Agriculture Organization of the United Nations, and WHO. 2016. “Kava: A Review of the Safety of Traditional and Recreational Beverage Consumption.”

Fu, Peter P., Qingsu Xia, Lei Guo, Hongtao Yu, and Po-Chuen Chan. 2008. “Toxicity of Kava Kava.” Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews 26 (1): 89–112. https://doi.org/10.1080/10590500801907407.

Gow, Paul J., Nathan J. Connelly, Richard L. Hill, Peter Crowley, and Peter W. Angus. 2003. “Fatal Fulminant Hepatic Failure Induced by a Natural Therapy Containing Kava.” The Medical Journal of Australia 178 (9): 442–43. https://doi.org/10.5694/j.1326-5377.2003.tb05286.x.

Jhoo, Jin-Woo, James P. Freeman, Thomas M. Heinze, Joanna D. Moody, Laura K. Schnackenberg, Richard D. Beger, Klaus Dragull, Chung-Shih Tang, and Catharina Y. W. Ang. 2006. “In Vitro Cytotoxicity of Nonpolar Constituents from Different Parts of Kava Plant (Piper Methysticum).” Journal of Agricultural and Food Chemistry 54 (8): 3157–62. https://doi.org/10.1021/jf051853j.

Lechtenberg, M., B. Quandt, M. Schmidt, and A. Nahrstedt. 2008. “Is the Alkaloid Pipermethystine Connected with the Claimed Liver Toxicity of Kava Products?” Die Pharmazie 63 (1): 71–74. https://www.ncbi.nlm.nih.gov/pubmed/18271308.

Li, X. Z., and I. Ramzan. 2010. “Role of Ethanol in Kava Hepatotoxicity.” Phytotherapy Research: PTR 24 (4): 475–80. https://doi.org/10.1002/ptr.3046.

Lüde, Saskia, Michael Török, Sandy Dieterle, René Jäggi, Karin Berger Büter, and Stephan Krähenbühl. 2008. “Hepatocellular Toxicity of Kava Leaf and Root Extracts.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 15 (1-2): 120–31. https://doi.org/10.1016/j.phymed.2007.11.003.

Moulds, Robert F. W., and Joji Malani. 2003. “Kava: Herbal Panacea or Liver Poison?” The Medical Journal of Australia 178 (9): 451–53. https://doi.org/10.5694/j.1326-5377.2003.tb05289.x.

Olsen, Line R., Mark P. Grillo, and Christian Skonberg. 2011. “Constituents in Kava Extracts Potentially Involved in Hepatotoxicity: A Review.” Chemical Research in Toxicology 24 (7): 992–1002. https://doi.org/10.1021/tx100412m.

Pantano, Flaminia, Roberta Tittarelli, Giulio Mannocchi, Simona Zaami, Serafino Ricci, Raffaele Giorgetti, Daniela Terranova, Francesco P. Busardò, and Enrico Marinelli. 2016. “Hepatotoxicity Induced by ‘the 3Ks’: Kava, Kratom and Khat.” International Journal of Molecular Sciences 17 (4): 580. https://doi.org/10.3390/ijms17040580.

“Re: Critical Analysis of Suspected Cases of Kava Hepatotoxicity: Kava Taken as Directed Is Rarely Hepatotoxic - American Botanical Council.” n.d. Accessed May 10, 2021. https://www.herbalgram.org/resources/herbclip/issues/bin_368/review120381-368/.

Rowe, Anthony, Lillian Yuan Zhang, and Iqbal Ramzan. 2011. “Toxicokinetics of Kava.” Advances in Pharmacological Sciences 2011 (March): 326724. https://doi.org/10.1155/2011/326724.

Russmann, Stefan, Yann Barguil, Pierre Cabalion, Marina Kritsanida, Daniel Duhet, and Bernhard H. Lauterburg. 2003. “Hepatic Injury due to Traditional Aqueous Extracts of Kava Root in New Caledonia.” European Journal of Gastroenterology & Hepatology 15: 1033–36. https://doi.org/10.1097/01.meg.0000085464.12407.7b.

Showman, Angelique F., Jonathan D. Baker, Christina Linares, Chrystie K. Naeole, Robert Borris, Edward Johnston, Jerry Konanui, and Helen Turner. 2015. “Contemporary Pacific and Western Perspectives on `awa (Piper Methysticum) Toxicology.” Fitoterapia 100 (January): 56–67. https://doi.org/10.1016/j.fitote.2014.11.012.

Singh, Yadhu N., and Ashwini K. Devkota. 2003. “Aqueous Kava Extracts Do Not Affect Liver Function Tests in Rats.” Planta Medica 69 (6): 496–99. https://doi.org/10.1055/s-2003-40658.

Sorrentino, L., A. Capasso, and M. Schmidt. 2006. “Safety of Ethanolic Kava Extract: Results of a Study of Chronic Toxicity in Rats.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 13 (8): 542–49. https://doi.org/10.1016/j.phymed.2006.01.006.

Stefan, U. 2009. “Toxic Hepatitis After Consumption of Traditional Kava Preparation.” Journal of Travel Medicine 16 (1). https://doi.org/10.1111/j.1708-8305.2008.00259.x.

Stickel, Felix, Hans-Martin Baumüller, Karlheinz Seitz, Dimitrios Vasilakis, Gerhard Seitz, Helmut K. Seitz, and Detlef Schuppan. 2003. “Hepatitis Induced by Kava (Piper Methysticum Rhizoma).” Journal of Hepatology 39 (1): 62–67. https://doi.org/10.1016/s0168-8278(03)00175-2.

Teschke, R., J. Fuchs, R. Bahre, A. Genthner, and A. Wolff. 2010. “Kava Hepatotoxicity: Comparative Study of Two Structured Quantitative Methods for Causality Assessment.” Journal of Clinical Pharmacy and Therapeutics 35 (5): 545–63. https://doi.org/10.1111/j.1365-2710.2009.01131.x.

Teschke, R., W. Gaus, and D. Loew. 2003. “Kava Extracts: Safety and Risks Including Rare Hepatotoxicity.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 10 (5): 440–46. https://doi.org/10.1078/0944-7113-00314.

Teschke, Rolf. 2010a. “Kava Hepatotoxicity--a Clinical Review.” Annals of Hepatology 9 (3): 251–65. https://doi.org/10.1016/S1665-2681(19)31634-5.

———. 2010b. “Kava Hepatotoxicity: Pathogenetic Aspects and Prospective Considerations.” Liver International: Official Journal of the International Association for the Study of the Liver 30 (9): 1270–79. https://doi.org/10.1111/j.1478-3231.2010.02308.x.

Teschke, Rolf, Alexander Genthner, and Albrecht Wolff. 2009. “Kava Hepatotoxicity: Comparison of Aqueous, Ethanolic, Acetonic Kava Extracts and Kava-Herbs Mixtures.” Journal of Ethnopharmacology 123 (3): 378–84. https://doi.org/10.1016/j.jep.2009.03.038.

Teschke, Rolf, Samuel X. Qiu, and Vincent Lebot. 2011. “Herbal Hepatotoxicity by Kava: Update on Pipermethystine, Flavokavain B, and Mould Hepatotoxins as Primarily Assumed Culprits.” Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 43 (9): 676–81. https://doi.org/10.1016/j.dld.2011.01.018.

Teschke, Rolf, Samuel X. Qiu, Tran Dang Xuan, and Vincent Lebot. 2011. “Kava and Kava Hepatotoxicity: Requirements for Novel Experimental, Ethnobotanical and Clinical Studies Based on a Review of the Evidence.” Phytotherapy Research: PTR 25 (9): 1263–74. https://doi.org/10.1002/ptr.3464.

Teschke, Rolf, Jerome Sarris, Xaver Glass, and Johannes Schulze. 2011. “Kava, the Anxiolytic Herb: Back to Basics to Prevent Liver Injury?: Kava, back to Basics?” British Journal of Clinical Pharmacology 71 (3): 445–48. https://doi.org/10.1111/j.1365-2125.2010.03775.x.

Teschke, Rolf, Jerome Sarris, and Vincent Lebot. 2011. “Kava Hepatotoxicity Solution: A Six-Point Plan for New Kava Standardization.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 18 (2-3): 96–103. https://doi.org/10.1016/j.phymed.2010.10.002.

———. 2013. “Contaminant Hepatotoxins as Culprits for Kava Hepatotoxicity--Fact or Fiction?” Phytotherapy Research: PTR 27 (3): 472–74. https://doi.org/10.1002/ptr.4729.

Teschke, Rolf, Jerome Sarris, and Isaac Schweitzer. 2012. “Kava Hepatotoxicity in Traditional and Modern Use: The Presumed Pacific Kava Paradox Hypothesis Revisited.” British Journal of Clinical Pharmacology 73 (2): 170–74. https://doi.org/10.1111/j.1365-2125.2011.04070.x.

Teschke, Rolf, Alexander Schwarzenboeck, and Karl-Heinz Hennermann. 2008. “Kava Hepatotoxicity: A Clinical Survey and Critical Analysis of 26 Suspected Cases.” European Journal of Gastroenterology & Hepatology 20 (12): 1182–93. https://doi.org/10.1097/MEG.0b013e3283036768.

Tugcu, Gulcin, Hasan Kırmızıbekmez, and Ahmet Aydın. 2020. “The Integrated Use of in Silico Methods for the Hepatotoxicity Potential of Piper Methysticum.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 145 (November): 111663. https://doi.org/10.1016/j.fct.2020.111663.

Yamazaki, Yuko, Hiroko Hashida, Anna Arita, Keiko Hamaguchi, and Fumio Shimura. 2008. “High Dose of Commercial Products of Kava (Piper Methysticum) Markedly Enhanced Hepatic Cytochrome P450 1A1 mRNA Expression with Liver Enlargement in Rats.” Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 46 (12): 3732–38. https://doi.org/10.1016/j.fct.2008.09.052.

Yang, Xi, and William F. Salminen. 2011. “Kava Extract, an Herbal Alternative for Anxiety Relief, Potentiates Acetaminophen-Induced Cytotoxicity in Rat Hepatic Cells.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 18 (7): 592–600. https://doi.org/10.1016/j.phymed.2011.02.006.
 
Top